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ABSTRACT 
(ENGLISH VERSION) 
 
The transcriptional co-activator TAZ, known Hippo transducer together with his 
paralogue YAP, has recently emerged as important player in processes like organ 
growth and tumorigenesis. Here we focused on two aspects of TAZ biology: the 
first regards the role of TAZ as molecular determinant of breast cancer stem cells 
(CSCs); the second is the characterization of TAZ as downstream mediator of 
Wnt signaling.  
In part 1, we show and discuss the discovery that more-malignant/CSC-
enriched primary breast cancers, compared to well-differentiated/non-metastatic 
tumors, display an elevated activity of TAZ, and that this correlates with a poorer 
prognosis. TAZ protein levels and activity are elevated in prospective CSCs and 
they increase during tumor evolution toward malignancy, both in vitro and in po-
orly-differentiated primary breast tumors. Moreover, TAZ is required to sustain 
self-renewal and tumor-initiation capacities of breast cancer cells. These features 
make TAZ a determinat of several characteristic of breast CSCs and a attractive 
molecule for therapy (this work was published last year, Cordenonsi et al., Cell 
2011). 
In part 2, we show that independently of the Hippo pathway, TAZ is regulated 
and trascriptionally-activated by the Wnt cascade, sheding lights on the modaliti-
tes by which cells respond to the Wnt growth factors. We found that, in the ab-
sence of Wnt activity, the components of the !-catenin destruction complex - 
APC, Axin and GSK3 - are also required to keep TAZ at low levels because 
phosphorylated !-catenin bridges TAZ to its ubiquitin ligase complex. Upon Wnt 
signaling, escape of !-catenin from the destruction complex impairs TAZ degra-
dation and leads to concomitant accumulation and activation of !-catenin and 
TAZ (this work was published this year, Azzolin and Zanconato et al., Cell 2012). 
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ABSTRACT 
(ITALIAN VERSION) 
 
Il co-attivatore trascrizionale TAZ, conosciuto per essere un trasduttore della via 
del segnale Hippo con il suo paralogo YAP, è recentemente emerso come impor-
tante fattore in processi quali la crescita degli organi e la tumorigenesi. In questo 
lavoro ci siamo focalizzati su due aspetti della biologia di TAZ: il primo riguarda 
il ruolo di TAZ come determinante molecolare delle cellule staminali del tumore 
al seno; il secondo, la caratterizzazione di TAZ come mediatore a valle della via 
del segnale Wnt. 
Usando un approccio bioinformatico, abbiamo scoperto che i tumori alla 
mammella più maligni e arricchiti in cellule staminali tumorali mostrano una più 
elevata attività di TAZ quando comparati ai tumori più differenziati e non meta-
statici (Parte 1): questo correla inoltre con una prognosi più sfavorevole. I livelli 
proteici e l’attività di TAZ sono elevati nelle putative cellule staminali tumorali e 
aumentano durante la progressione dei tumori verso la malignità, sia in vitro che 
nei tumori primari. In più, TAZ è richiesto per sostenere il rinnovamento e la ca-
pacità di formare tumori in vivo da parte delle cellule tumorali mammarie. Queste 
proprietà rendono TAZ un determinante di parecchie caratteristiche di cellule 
staminali tumorali mammarie e una molecola interessante dal punto di vista tera-
peutico. 
Abbiamo inoltre studiato i regolatori a monte di TAZ e abbiamo scoperto che, 
indipendentemente dalla via del segnale Hippo, TAZ è regolato dalla via del se-
gnale Wnt (Parte 2), che ne promuove anche l’attivazione. Questo meccanismo 
chiarisce una delle modalità attraverso cui le cellule rispondono alle citochine del-
la famiglia Wnt. Dal punto di vista meccanicistico, in assenza del segnale Wnt, i 
componente del complesso di distruzione di !-catenina - APC, Axin and GSK3 – 
sono richiesti per mantenere bassi i livelli di TAZ: questo è dovuto al fatto che !-
catenina fosforilata fa da ponte tra TAZ e il suo complesso di ubiquitina ligasi. In 
seguito al segnale Wnt, !-catenina non è più fosforilata nel complesso di distruzi-
one e ciò impedisce la degradazione di TAZ: di conseguenza vi è un contempora-
neo accumulo sia di TAZ che di !-catenina. 
 6 
 
 7 
PUBLICATIONS 
 
 
Michelangelo Cordenonsi, Francesca Zanconato, Luca Azzolin, Mattia Forcato, 
Antonio Rosato, Chiara Frasson, Masafumi Inui, Marco Montagner, Anna R. Pa-
renti, Alessandro Poletti, Maria Grazia Daidone, Sirio Dupont, Giuseppe Basso, 
Silvio Bicciato, and Stefano Piccolo (2011). The Hippo transducer TAZ con-
fers cancer stem cell-related traits on breast cancer cells. Cell 147, 759–772 
 
 
Luca Azzolin, Francesca Zanconato, Silvia Bresolin, Mattia Forcato, Giuseppe 
Basso, Silvio Bicciato, Michelangelo Cordenonsi, and Stefano Piccolo (2012). 
Role of TAZ as mediator of Wnt signaling. Cell 151,1443-1456 
 
 
 
This work was realized under the mentorship of Prof. Michelangelo Cordenonsi 
and in close collaboration with Dr. Francesca Zanconato.  
 8 
 9 
INTRODUCTION 
 
Solid tumors resemble developing organs: they are a complex ensemble of 
different subtypes of tumor cells, at different degrees of differentiation, mixed 
with stromal cells and extracellular matrix (ECM); Moreover, solid tumors hijack 
cell signaling events normally regulating development, tissue repair, remodelling 
and regeneration (Egeblad et al., 2010). As such, thinking of tumors as complex 
organs might allow a more profound understanding of the events that governs tu-
mor initiation, evolution toward malignancy and, eventually, metastasis.  
 
Stem cells and cancer 
The Cancer Stem Cell (CSC) model of tumor development and progression states 
that tumors, like normal adult tissues, are organized in cell hierarchy and contain a 
subset of cells that both self-renew and give rise to differentiated progeny 
(through symmetric and asymmetric division) (Visvader and Lindeman, 2008). As 
in other tissues, stem cells are a minority of the whole organ, and are the only 
cells that can virtually maintain tumor growth indefinitely. The remaining cells, 
though actively proliferating and making up the bulk of the tumor, are also diffe-
rentiating and destined to die. The self-renewal properties of the CSCs are thus 
the real driving force behind tumor growth. Stem cells have become increasingly 
relevant to cancer research since 1994, when the existence of tumor-initiating 
cells was demonstrated for human acute myeloid leukaemia (Lapidot et al., 1994): 
in particular, this small subset of cancerous blood cells, identified on the basis of 
their phenotypical similaritites to normal hematopoietic stem cells, could propa-
gate the disease in mice. Tumor-initiating cells have then been dubbed CSCs be-
cause of their pluripotency - meaning they are able to create all of the other cells 
in the tumor, much like blood stem cells behave in bone marrow. Even if it has 
been harder to test whether CSCs fuel the growth of tumors in other tissues, popu-
lation of cells with stem-like properties have then been described also for breast 
(Al-Hajj et al., 2003), brain (Singh et al., 2004), prostate (Collins et al., 2005), co-
lon (Ricci-Vitiani et al., 2007) and pancreatic (Li et al., 2007) cancers and others 
(reviewed in Visvader and Lindeman, 2008 and Baccelli and Trumpp, 2012). The 
 10 
overall procedure for the isolation of CSCs was rather similar across these studies: 
fractionation of tumor cells using cell-surface markers characteristic of stem cells, 
followed by implantation into immunocompromized mice to assess xenograft 
growth. Very often, CD133 or CD44 cell surface marker were employed to purify 
CSCs in the previuos studies (Baccelli and Trumpp, 2012). 
Located at the top of the tumor hierarch, CSCs divide to create a duplicate copy of 
themselves that remains undifferentiated (a process called self-renewal) or a dau-
ghter cell (called a multipotent progenitor) which subsequently differentiates into 
the various cells that make up the tumor. These tumor cells then replicate in an er-
ratic and invasive manner. Despite the fact that are relatively rare, CSCs appear to 
be driving the disease (reviewed in Nguyen et al., 2012). Conventional chemothe-
rapy or radiotherapy are directed against the bulk population of tumor cells, at-
tempting to kill as many cancer cells as possible (Dean et al., 2005). Unfortuna-
tely, not only do these treatments often damage healthy tissues in the process, but 
they may be missing CSCs. Even if the tumor is eliminated, few CSCs that survi-
ve can recreate the original tumor over time - the best explanation we have for 
why relapse can occur after years of remission. CSC resistance might be caused 
by increased drug efflux capacities, mediated by expression of the multidrug resi-
stance transporters (Dean et al., 2005), or by radiation-induced reactive oxygen 
species scavenging, as couterbalance mechanism to radiotherapy (Diehn et al., 
2009). As such, a combined therapy that target also CSCs would be greatly desi-
rable. It would be therefore auspicable to find the suitable “Achille’s heel” of 
CSCs, particularly in the mechanisms (i.e., signaling pathways) that sustain CSCs 
themselves, in order to sensitize them to therapy. 
Beside these properties, CSCs are operationally defined as cells having some pe-
culiar characteristics. In vitro culture in unattached conditions where cells grow as 
round spheres is routinely used for enrichment and propagation of stem cells and 
number of spheres emerging from dissociated tumor samples is used as bona fide 
reflection of their CSC content (Dontu et al., 2003). Xenotransplantation assays 
have been used to prove cancer stemness: indeed, serial transplantation of CSC-
enriched populations into animal models should re-establish the phenotypic het-
erogeneity evident in the primary tumors and exhibit self-renewing capabilities on 
serial passages. 
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However, the definition of CSCs remains largely operational and based on func-
tional assays that register self-renewal in vitro and tumor initiation in vivo. More 
specifically, we lack molecular mechanisms responsible for the special attributes 
of CSCs. 
 
Breast tumors 
Tumor progression is a chain of cellular and molecular events that occur gradually 
during the development of neoplasia. During this process, tumors can undergo 
evolution to overcome organism defense and become more and more aggressive, 
but how this occurs is only partially understood. Breast cancer is the most com-
mon malignant disease in Western women. In these patients, the main cause of 
death is the metastasis spreading and not the primary tumors, that nowadays can 
be early diagnosed by mass screening. As a consequence, improving our under-
standing about the molecular mechanisms of the cells, i.e. CSCs, able to drive tu-
mor formation and metastasis within breast cancers, might provide new prognos-
tic markers or therapeutic targets and also improve clinical management of the 
disease. 
A wide range of histopathological subtypes of breast tumors have been identified, 
as well as associated prognostic markers or features (Weigelt et al., 2005). Pa-
thologists have classically distinguished three kinds of tumors: grade 1 (G1), 
grade (G2) and grade 3 (G3) tumors. G1 tumors form tubular structures, like nor-
mal mammary gland, and are low proliferating. At contrary, in histological prepa-
rations, G3 cancers have lost any sign of differentiation and display a large num-
ber of mitotic figures, indicating an active proliferation. Not surprisingly, G3 tu-
mors are associated with malignancy and high risk of metastasis occurrence in 
breast cancer patients, while patients with G1 tumors have a better clinical out-
come. Instead, G2 cancers display intermediate characteristics between G1 and 
G3. 
Many studies have identified subpopulations (Al-Hajj et al., 2003; Sheridan et al., 
2006; Grimshaw et al., 2008) of cells within breast tumors that are able to recreate 
the tumor tissue after injection in immunocompromised mice, and that have been 
classified as CSCs. In this framework, more recently, it has been shown that G3 
breast tumors display a higher content of CSCs with respect to G1, and this could 
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account to their more aggressive phenotypes (Pece et al., 2010), demonstrating 
that heterogeneous phenotypical and molecular traits of human breast cancers is a 
direct reflection of their CSC content. However, how cells can acquire CSC prop-
erties is still a matter of debate. 
 
The Hippo pathway 
The Hippo pathway (Figure 1) is a tumor suppressor signaling cascade that has 
emerged as an important regulator of organ growth, tissue regeneration, embry-
onic development, and stem cell compartment in epitelia (Pan, 2010). It was first 
identified in Drosophila melanogaster (Figure 1A, left panel): indeed, from ge-
netic screenings aimed at finding regulators of tissue growth (Harvey et al., 2003; 
Jia et al., 2003; Justice et al., 1995; Tapon et al., 2002; Udan et al., 2003; Wu et 
al., 2003; Xu et al., 1995), it was discovered that loss of the central kinases Hippo 
(Hpo) and Warts (Wts) results in overgrowth of the imaginal discs and of the cor-
responding adult organs. The pathway was named Hippo «because of the dark, 
folded and overgrown cuticle of the mutant [flies] heads» (Udan et al., 2003), that 
resembled an hippopotamus (Figure 1B). The mechanism of Hpo and Wts action 
in Drosophila has been then extensively studied (Figure 1A, left panel). When the 
pathway is active, Hpo in complex with its co-factor Salvador (Sav) phosphoryla-
tes Wts and its co-factor Mats (Mob-as-a-tumor-suppressor; Lai et al., 2005), 
promoting the activation of Wts kinase activity. Activated Wts/Mats complex 
phosphorylates the trascriptional co-activator Yorkie (Yki), favouring its retention 
in the cytoplasm by interaction with 14-3-3 proteins (Ren et al., 2010). Conver-
sely, when the pathway is inactive, Yki can freely accumulate in the nucleus and 
induce the expression of target genes, that promote cell proliferation and survival 
(reviewed in Halder and Johnson, 2011 and Mauviel et al., 2011). Because Yki 
lacks an intrinsic DNA-binding activity, its target specificity is dictated by 
interaction with other factors, mainly Scalloped (Sd). Genetically, overexpression 
of Yki phenocopies loss of function mutations of Hpo or Wts, including tissue o-
vergrowth in wing imaginal discs (Huang et al., 2005). Thus, Yki is a growth 
promoter, whereas Hpo, Sav, Wts and Mats act as tumor suppressors by limiting 
the growth-promoting activity of Yki. 
The core Hippo signaling pathway is conserved also in mammals (Figure 1A, 
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right panel). Aided by the adaptor proteins SAV1/WW45 (Sav in D. mela-
nogaster) and MOBKL1A/B (collectively known as MOB1; Mats in D. mela-
nogaster), the MST1/2 (Hpo in D. melanogaster) kinases phosphorylate and acti-
vate the NDR family kinases LATS1/2 (Wts in D. melanogaster) (Chan et al., 
2005), that in turn phosphorylate the mammalian orthologs of Yki, YAP (Yes-
associated protein) (Dong et al, 2007; Zhao et al., 2008) and TAZ (transcriptional 
coactivator with PDZ-binding motif, also known as Wwtr1) (Lei et al., 2008). 
LATS1/2-mediated phosphorylation of YAP/TAZ on multiple residues (S61, 
S109, S127, S164, S381 for human YAP, and S66, S89, S117, S311 for human 
TAZ) inhibits YAP/TAZ activity through different mechanisms. Phosphorylated 
YAP on S127 or TAZ on S89 are retained in the cytoplasm by interaction with 
14-3-3 proteins (Kanai et al., 2000; Basu et al., 2003). Moreover, phosphorylation 
of YAP on S381 or TAZ on S311 serves as priming event for successive pho-
sphorylation by Casein Kinase (CK) 1 #/$ and creation of a phosphodegron motif, 
that tags the proteins to E3 ubiquitin ligase SCF!
-TrCP
 recognition and subsequent 
ubiquitin-mediated proteasomal degradation (Liu et al., 2010; Zhao et al., 2010). 
When the Hippo cascade is inactive, YAP and TAZ are free to accumulate in the 
nucleus and activate gene-target transcription. However, because they lack any 
DNA-binding domain, YAP and TAZ function as transcriptional co-activators and 
they interact with a range of DNA-binding transcription factors, such as the TE-
AD/TEF family transcription factors (TEAD1/2/3/4), the p53-family member p73, 
the Runt family members Runx1 and Runx2, Pax3, Pax8, the thyroid transcription 
factor-1 (TTF1), TBX5, the peroxisome proliferator-activated receptor " (PPAR"), 
and SMAD1/2/3/4 (reviewed in Pan, 2010 and Mauviel et al., 2011). Among the-
se YAP/TAZ interacting transcription factors, TEAD1-4, which represent the or-
thologs of the Drosphila Sd protein, have emerged as the prime mediators of 
YAP/TAZ function (Zhao et al., 2008; Ota and Sasaki, 2008). 
A large number of proteins have been implicated to act upstream of and 
regulate the Hippo pathway through MST/LATS-dependent mechanisms, both in 
Drosophila and in mammals (Figure 1A). These include: the FERM domain pro-
teins Merlin (McCartney et al., 2000) and Expanded; the atypical cadherins Fat 
and Dachsous; the transmembrane polarity-regulator Crumbs (Robinson et al., 
2010); the cell polarity factors Lethal giant larvae (Lgl), Discs large (Dlg), Scrib-
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ble (Scrib);  Jub (Ajuba LIM proteins in mammals); the Ras association family 
protein RASSF (reviewed in Zhao et al., 2011a). Other regulators have been iden-
tified only in mammals: the Crumbs complex-associated protein PALS1 (Varelas 
et al., 2010), Angiomotin (AMOT) (Zhao et al., 2011b), and the tight junction 
protein ZO-2 (Oka et al., 2010; Remue et al., 2010). In recent years, however, va-
riations on the classical Hippo view have emerged, including LATS-independent 
phosphorylation of YAP/TAZ, MST-independent activation of LATS, and pho-
sphorylation-independent modalities of YAP/TAZ controls. These include the re-
gulation by: the adherent juction-associated protein %-catenin (Schlegelmilch et 
al., 2011; Silvis et al., 2011); KIBRA (Moleirinho et al. 2012) and mechanical 
cues (Dupont et al., 2011; Halder et al., 2012). 
The physiological relevance of the Hippo pathway was supported by gene-
tic studies in mice. In mouse liver, transgenic overexpression of YAP (Dong et al., 
2007; Camargo et al., 2007) or liver-specific knockout of Mst1/2 or Sav1 (Zhou et 
al., 2009; Lee et al., 2010; see Figure 1C)  promote organ enlargment, hyperplasia 
and tumor development. Further confimations come from experiments in mouse 
heart, where Sav1 (Figure 1D), Mst1/2 or Lats2 conditional depletion leads to he-
art enlargement or cardiomegaly throught a mechanism that was unlikely to be 
due to elevated cardiac progenitor number, but rather to an increase in the tran-
scriptional cooperation between YAP and !-catenin to regulate common target 
gene (Heallen et al., 2011). Similar results are obtained for pancreas and intestine, 
where transgenic overexpression of YAP leads to a potent expansion of progenitor 
cells and loss of differentiation (Camargo et al., 2007). However, using a different 
driver for YAP induction, the same authors have more recently found that YAP 
suppresses intestinal renewal and overgrowth by inhibiting Wnt signaling pa-
thway (Barry et al., 2012). This is also in contrast with the finding that intestine-
specific knockout of Mst1/2 caused marked expansion of an undifferentiated stem 
cell compartment and loss of secretory cells throughout the small and large inte-
stine in a YAP-dependent manner (Zhou et al., 2011).  
 
The Hippo pathway in tumorigenesis 
Consistent with the critical role of Hippo signaling in mammals, deregulation or 
mutation in the Hippo pathway components have been linked to cancer. Merlin is 
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a tumor-suppressor protein of the ERM family encoded by the NF2 gene that con-
trols cell growth and contact-dependent inhibition of proliferation and that have 
been characterized as Hippo regulator (Zhang et al., 2010). Mutations in the NF2 
gene are the underlying cause of neurofibromatosis type 2 (NF2), a familial cancer 
syndrome characterized by the development of sporadic tumors of the nervous 
system (Bourn et al., 1994). Although mutations in other Hippo pathway compo-
nents are understudied or not common (Pan, 2010), it is evident the involvement 
of this pathway in tumorigenesis. Indeed, downregulation or inactivation of 
MST1/2, MOB1 or LATS1/2 (tumor suppressor components of the pathway) have 
been shown by many authors in different human cancers. As the most downstream 
effectors, it is not surprising that YAP and TAZ function as tumor promoters. 
YAP has been implicated as the candidade oncogene in human chromosome 
11q22 amplicon, and indeed amplification of this locus has been identified in hu-
man hepatocellular carcinomas (Zender et al., 2006), in breast cancers (Overhol-
tzer et al., 2006) and other cancers (reviewed in Pan, 2010 and Zhao et al., 2010). 
Moreover, comprehensive survey of the most common solid cancer types revealed 
widespread and frequent YAP and TAZ overexpression (Pan et al., 2010). Consi-
stent with these findings, overexpression of YAP or TAZ can induce anchorage-
independent growth and epithelial-to-mesenchymal transition of mammary cells 
(Overholtzer et al., 2006; Chan et al., 2008; Lei et al., 2008; Zhao et al., 2008).  
 
YAP/TAZ and Stem Cells 
Emerging studies indicate that YAP and TAZ might contribute to the regulation 
of stem cell and progenitor cell self-renewal and expansion, as well as embryonic 
development. 
 In the preimplantation mouse embryo, the inner more-compacted cells 
display an increased cytoplasmic TAZ/YAP localization, which allow the expres-
sion of Oct4 and inner cell mass (ICM) specification. Conversely, in the less-
compacted outer cells TAZ/YAP remain nuclear: this promote Cdx2 expression, 
and thereby the trophoblast cell lineage (Nishioka et al., 2009). As proof of prin-
ciple, disruption of LATS1/2 kinase activity in the ICM favors its conversion to 
trophoblast (Nishioka et al., 2009). The critical roles of YAP and TAZ are further 
highlight by the knockout mice. Yap deletion causes embryo lethality due to failu-
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re in chorioallantoic fusion (Morin-Kenscki et al., 2006), with no significant ab-
normalities in preimplantation stages or trophoectoderm specification, a pheno-
type that can be ascribed to TAZ redundant function. Also TAZ knockout mice 
mainly die in utero in the post-implantation stage and develop polycystic kidney 
disease (Makita et al., 2008). However, whereas loss of either YAP or TAZ alone 
does not lead to abnormalities in preimplantation development (Morin-Kenscki et 
al., 2006; Hossain et al., 2007; Makita et al., 2008), Yap
-/-
Taz
-/-
 embryos die before 
the morula stage, prior to the establishment of inside and outside cell populations 
(Nishioka et al., 2009), confirming their fundamental role in development. 
 In human embryonic stem cells (ESCs) nuclear TAZ is required to maintain 
self-renewal markers (Varelas et al., 2008); likewise, YAP is necessary to sustain 
pluripotency in mouse ESCs (Lian et al., 2010; Qin et al., 2012) and important for 
reprogrammig of mouse fibroblasts to an induced pluripotent stem cell (IPS) state 
(Qin et al., 2012). 
For instance, YAP expression is generally restricted to the progenitor cells in 
normal mouse intestine, and transgenic expression of YAP in mouse intestines 
causes a marked expansion of the progenitor cell compartment (Camargo et al., 
2007). Similarly, YAP expression expands basal epidermal undifferentiated 
stem/progenitor cells in mouse skin (Schlegelmich et al., 2011); moreover it su-
stain in vitro colony forming capacity of these cells and their ability to seed tumor 
in grafting experiment (Schlegelmich et al., 2011). Conversely, conditional kno-
ckout of YAP in mouse skin leads to decreased proliferation of basal cells, thinner 
epidermis and failure of skin expansion (Schlegelmich et al., 2011). 
In chick embryos, YAP (or TEAD) gain-of-function caused a marked expansion 
of the neural progenitor population, by increasing their proliferation and inhibiting 
their differentiation (Cao et al., 2008). 
These observations reflect a role of TAZ/YAP in maintaining the balance between 
stem, progenitor and differentiated cells. 
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PART 1 
 
Signaling pathways are central events by which cells respond to chemical 
or physical stimuli (Engeblad et al., 2010). As many of them are often subverted 
by cancers, we were interested in understanding what pathways were differen-
tially regulated in G3 versus G1 breast tumors, in order to try to explain tumor 
progression and heterogeneity and the CSCs enrichment in G3 tumors (Pece et al., 
2010). This would provide molecular explanation for CSCs origin and main-
tainance and possible targets for therapy. 
 
RESULTS 
TAZ is significantly upregulated in G3 tumors compared to G1 
To gain inside the differences between G1 and G3 breast cancers, we decided to 
use a biostatistics approach in collaboration with the group of prof. Silvio Bic-
ciato, University of Modena. We generated a compendium of data (metadataset) 
from 7 independent breast cancer gene expression-datasets that also contained in-
formation on histological grading and outcome (Table 1; see also Experimental 
Procedures). This cohort of data, relative to 993 primary tumors, was analyzed by 
the Significance Analysis of Microarrays (SAM) algorithm to identify a list of ge-
nes differentially expressed in G3 versus G1 tumors. Out of these, we found that 
78 Affymetrix probesets were specifically up-regulated in G3 tumors compared to 
G1 (schematic representation of the experiment in Figure 2A; the list of up-
regulated probesets in G3 cancers is provided in Table 2). We next tested the sta-
tistical association between this list of genes and lists of genes, named signatures, 
that highlight activation of specific signaling pathways, such as YAP/TAZ, Notch, 
Ras, STAT3, ErBB2, Wnt/!-catenin, TGF-!, in mammary cell lines (Figure 2A 
and B). This association was accessed by testing if the proportion of genes of a 
signature in the list of G3-over-expressed genes was significantly different from 
what would be expected by chance. Thus, a p-value smaller than 5% indicated a 
statistically significant enrichment of genes that are target of a specific signaling 
pathway in G3 tumors. Strikingly, only signatures for the activity of YAP and 
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TAZ emerged as significantly over-represented among the genes over-expressed 
in G3 samples (Figure 2B). In other words, G3 breast tumors express a large sub-
set of YAP/TAZ target genes, suggesting the possibility that TAZ and/or YAP get 
activated more in G3 than in G1 tumors. As previously reported, G3 breast tumors 
are also characterized by a high expression of embryonic and normal mammary 
stem cell signatures (Ben-Porath et al., 2008; Pece et al., 2010) (Figures 2B and 
C), suggesting that TAZ/YAP activity correlates with stemness potential. All to-
gether, these findings indicate that tumors classified as poorly differentiated/high 
grade by histopathological criteria, and as enriched of stemness traits by molecu-
lar profiling, in fact display elevated YAP/TAZ activity.   
To corroborate the link between YAP/TAZ activation and phenotypic 
manifestations of CSCs in primary tumors, we decided to examine tumor hetero-
geneity and metastasis. Indeed, it has been proposed that breast cancer heteroge-
neity may be explained, at least in part, by the proportion/content of CSCs within 
each tumor (Pece et al., 2010). In this respect, G2 tumors, whose characteristics in 
terms of gene-expression and clinical outcome can vary from being similar to G1 
to closer to G3 (Ivshina et al., 2006), can be assumed as example of a heterogene-
ous category of breast cancers. We stratified G2-patients in two categories, with 
High or Low expression of the YAP/TAZ signature respectively, and tested if 
these two groups also displayed differential expression of stem cell signatures. In-
terestingly, G2 tumors stratified by high-YAP/TAZ activity were associated to an 
enrichment of stem cells' signatures, as proved for G3 cancers, whereas G2 tu-
mors stratified by low-YAP/TAZ activity were more similar to G1 tumors, that is, 
with a low expression of stem cell signatures (Figure 2C). This at least suggests 
that YAP/TAZ activity reflects the degree of CSCs representation in G2 tumors. 
Metastases are considered the most dramatic manifestation of tumor-initiating ca-
pacity of a primary tumor (Chaffer et al., 2011a), because only cells with stem-
like capacities are thought to be able to migrate and colonize distant organs. We 
therefore tested if YAP/TAZ activity was associated to this type of event in our 
metadataset. By univariate Kaplan-Meier analyses, tumors with high expression 
of the YAP/TAZ signature displayed a significantly higher probability to develop 
metastasis and reduced survival than tumors marked by low YAP/TAZ activity 
(Figure 2D). Taken together, the data support the notion that activation of TAZ 
and/or YAP specifically parallels with tumor traits previously linked to their CSC 
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content, such as high histological grade, tumor heterogeneity and metastasis. 
 
Malignant cells express more TAZ than their non-malignant counterparts 
We verified the previous conclusions in a cellular context by using two isogenic 
derivates of the human mammary MCF10A cell line: Ras-transformed MCF10A-
T1k cells (hereafter MII) and their malignant derivative, MCF10A-CA1a cells (al-
so known as MIV), derived from in vivo spontaneous evolution of MII cells (San-
tner et al., 2001) (Figure 3A). To validate MII and MIV cells as model of increa-
sed CSC content during malignant evolution of breast cancer (Pece et al., 2010), 
we compared their self-renewal potential, as assayed by their capacity to form 
and propagate mammospheres in vitro and to give rise to tumors in vivo when 
transplanted in the mouse fat pad (Dontu et al., 2003; Visvader and Lindeman, 
2008). In the mammosphere assay, we can measure the stem-like properties of 
cells by evaluating their growth capability in non-adherent non-differentiating cul-
ture conditions: indeed, under these conditions, only cells with stem-like proper-
ties can initiate the formation of floating spherical colonies, called mammos-
pheres, in which the mammosphere-initiating cells can undergo self-renewal, thus 
producing other mammosphere-initiating cells, and give rise to differentiated 
progeny, which instead constitute the bulk of the mammospheres (Dontu et al., 
2003). Once cultured in suspension, MIV cells formed more primary and 6-times 
more secondary mammospheres than MII cells (Figure 3B). The sphere-forming 
capacity in subsequent serial passages remained stable for MIV cells but declined 
for MII cells  (Figure 3B). Orthotopic transplantations were used to evaluate tu-
mor initiation: in this type of assay, we can assume that only cells endowed with 
stem-like properties can seed tumors. When injected orthotopically in the fat pad 
of immunocompromised mice, MII cells are tumorigenic, but non-malignant, and 
form tumors with “G1-like” characteristics, while MIV cells are metastatic and 
show properties analogous to G3 cancers (Figure 3C). In order to measure tumo-
rigenicity, we therefore decided to inject orthotopically 10
4
 and 10
6
 MII or MIV 
cells. While both concentrations of MIV cells readily formed tumors in all injec-
ted mice, MII-derived tumors were detected only in one-third of mice injected 
with 10
6
 cells but not at the lower cell concentration (Figure 3D). Thus, MII and 
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MIV cells are endowed with significantly different self-renewal and tumorigenic 
potential, recapitulating the differences in CSC representation previously descri-
bed also between G1 and G3 tumors. Injection in the mouse mammary fat pad of 
control and engineered cells was carried out in collaboration with prof. Antonio 
Rosato; histological examinations were carried out in collaboration with prof. An-
na Parenti. 
We next asked wheter this difference between MII and MIV could be ascribed to 
differential expression of TAZ and/or YAP and by western blot analysis we found 
that TAZ protein levels are higher in MIV cells compared to MII (Figure 3E), 
with no significant changes in YAP levels. As comparison, we also examined 
MDA-MB-231 cells, which are human metastatic breast cancer cells, commonly 
used in breast cancer research (Adorno et al., 2009): this cell line diplayed TAZ 
levels comparable to those of MIV (Figure 3E), suggesting that an increase in 
TAZ protein might be characteristic of more malignant cells. 
To directly address the role of TAZ as stemness determinant in our model of bre-
ast cancer, we knocked down endogenous TAZ by shRNAs in MIV cells. TAZ 
knockdown downregulated the expression of CTGF, a known TAZ/YAP target 
gene (Pan, 2010) (Figure 3F), but had no overt effects on cell viability and proli-
feration in 2D cultures (data not shown). Remarkably, however, MIV-shTAZ 
formed significantly less primary and secondary mammospheres than control 
MIV cells (MIV-shControl) (Figure 3G). To exclude possible off-target effects of 
our RNA interference approach, we co-infected MIV-shTAZ with a shRNA-
insensitive mouse TAZ construct, or EGFP as a control: in this experiments, only 
re-expression of TAZ rescued TAZ-dependent gene responses and mammosphere-
forming abilitites (Figure 3H and I). 
 To assay if TAZ regulates tumor-initiating potential of MIV cells, we compared 
MIV-shControl and MIV-shTAZ cells for their capacity to seed tumors at limiting 
dilutions. While shControl cells are able to form tumors in the majority of injected 
mice, even upon injection of only 20 cells, TAZ depleted cells showed a dramatic 
decrease of tumor seeding ability, as up to 10
4
 cells were required to induce tu-
mors in 100% of the animals (Figure J). Taken together, these in vitro and in vivo 
results indicate that TAZ is required for self-renewal and tumor initiation of 
highly-malignant MIV breast cancer cells. 
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TAZ confers self-renewal capacities to breast cancer cells 
A peculiar property of CSCs is the expression of specific cell surface markers that 
allow their selective isolation by fluorescence-activated cell sorting (FACS). In 
human, CD24
low/-
CD44
high
 has been suggested to define a population of cells that 
contain breast CSCs (Al-Hajj et al, 2003; Sheridan et al., 2006; Grimshaw et al., 
2008). Therefore, we decided to examine if these surface markers could identify a 
CSC population in our cell lines and if manipulating TAZ level we could modify 
this compartment. First, we analyzed parental MII: we identified and sorted out 
two different subpopulations, which we called CD44
low
 and CD44
high
, on the basis 
of CD44 staining, while CD24 staining was uniformly low or negative (Figure 
4A). The majority (&65%) of the cells was CD44low (Figure 4A), expressed low 
level of TAZ and of TAZ-target CTGF (Figure 4B), and after 2-week in vitro-
culture give rise to the same CD44
low
 cell population (Figure 4A). On the other 
hand, approximately 30% of the original population was CD44
high
 (Figure 4A), 
displayed a higher level of TAZ protein and, as a consequence, of CTGF (Figure 
4B), and after 15 days of in vitro culture could recapitulate the entire MII popula-
tion (Figure 4A), indicating that the CD44
high
 cells possess both self-renewal and 
differentiative capacities. Moreover, the CD44
high
 population included the so-
called ‘‘side population (SP)’’ (Figure 4C), which is defined by its ability to ex-
clude the Hoechst vital dye (Dontu et al., 2003). We further confirmed this obser-
vation by culturing the two cell population in mammosphere-forming conditions 
and saw that the CD44
high
-sorted population could give rise to more mammos-
pheres than the CD24
low
 counterpart (Figure 4D). In summary, we identified in 
MII cells a subpopulation of cells with CSC-like properties that display a higher 
level and activity of TAZ. 
To establish whether TAZ is functionally relevant for the biological traits of the 
CD44
high
CD24
low
 population, we knocked down endogenous TAZ in MII cells u-
sing three independent shRNAs (Figure 4E). TAZ is required for the maintenance 
of the CD44
high
CD24
low
 antigen phenotype (Figure 4F) and for primary and se-
condary mammosphere formation in MII cells (Figure 4G). 
To examine the functional consequences of TAZ overexpression in breast cancer 
cells, we genetically increased TAZ level in MII cells. We overexpressed a consti-
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tutive active TAZ mutant in MII cells, TAZ S89A. This is a LATS phosphomu-
tant, that impairs TAZ interaction with 14-3-3 protein and therefore TAZ retention 
in the cytoplasm (Kanai et al., 2000). Cells overexpressing TAZ, compared to 
controls (empty vector), developed a spindle-shaped morphology characteristic of 
cell transformation and EMT, as reported by others in different mammary cell 
lines (Chan et al., 2008). Enhancing TAZ caused the activation of TAZ target 
genes, such as CTGF, Survivin, PAI1 (Figure 5A), loss of E-cadherin expression 
(Figure 5A), but no differences in cell proliferation (data not shown). Compared 
to controls, TAZ-overexpressing MII cells were able to form more generations of 
mammospheres, indicating that they comprise a higher amount of cells with self-
renewal capability, i.e. stem cells (Figure 5B). Moreover, we found that the TAZ 
overexpression caused the conversion of all MII cells into cells with a unique 
CD44
high
-profile population (Figure 5C), i.e. CSCs. Interestingly, also MDA-MB-
231, metastatic cells and therefore highly enriched in CSCs, shared the same 
CD44
high
 profile (Figure 5C). In conclusion, we believed that TAZ can promote a 
CSCs phenotype.  
Next we wanted to show whether TAZ is per se sufficient to endow CSC-like 
properties to non-CSCs (i.e. CD44
low
CD24
low
 cell population). To do this, we first 
transduced MII with lentiviral vectors encoding for a doxycycline-inducible 
TAZ(S89A), or EGFP as control. From the transduced MII cells, CD44
low
CD24
low
 
(non-stem) and CD44
high
CD24
low
 populations were FACS-sorted, cultured in the 
presence or absence of doxycycline and assayed for mammosphere formation (Fi-
gure 5D). As control, induction of EGFP did not modify the mammosphere-
forming capacitites of neither CD44
low
CD24
low
 (Figure 5E, compare lanes 1 and 
3) nor CD44
high
CD24
low
 (compare lanes 2 and 4) subpopulations. Remarkably, in-
duction of TAZ(S89A) in non-stem CD44
low
CD24
low
 population promoted abun-
dant secondary mammosphere formation (Figure 5E, compare lane 5 and 7). Mo-
reover, TAZ(S89A) activation induced more self-renewal properties also to the 
putative stem CD44
high
CD24
low
 population (Figure 5E, compare lanes 6 and 8). 
These findings suggest that TAZ activity can confer attributes of self-renewal to 
the more differentiated progeny of prospective CSC populations. 
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TAZ confers resistance to chemotherapy to breast cancer cells 
Another peculiar characteristic of CSCs is their capacity to resist to chemotherapy 
and, as a consequence, to give rise to recurrence. We noticed that TAZ overe-
xpression in MII cells correlated with an increased in the activity of the multidrug 
resistance pumps, responsible for the drug elimination from the cell's cytoplasm, 
as measured by an increase of the SP by FACS (Figure 6A and B), i.e. the popula-
tion with “Low” Hoestch accumulation due to efficient extrusion. Accordingly, 
TAZ-expressing cells were more resistant than control cells to Paclitaxel (Figure 
6C) and Doxorubicin (Figure 6D), two widely used chemotherapeutic drugs. This 
is in line with the recently reported dependency of MDA-MB-231 cells on TAZ 
for Taxol resistance (Lai et al., 2011). 
 
TAZ Promotes High-Grade Breast Cancers 
As we show that TAZ protein level correlates with self-renewal and tumorigenic 
potential in our MII-MIV cellular model and molecularly determines characteri-
stic of CSCs, we used immunohistochemistry to compare TAZ expression in 26 
G1 primary breast tumors and 44 G3 invasive ductal carcinomas. In G1 tumors, 
TAZ expression was typically hardly detectable and only few cells appeared posi-
tive (Figures 7A and B). In contrast, the vast majority of G3 tumors (80%) contai-
ned a substantial fraction of cells displaying an intense TAZ nuclear staining (Fi-
gures 7A and C). Thus, G3 breast cancers are enriched with TAZ-positive cells, a 
finding that links the increased CSC content of high-grade tumors (Pece et al., 
2010) with the present functional characterization of TAZ as a promoter of CSC-
like traits. 
Moreover, as functional validation of the previous in vivo finding, gain-of-TAZ in 
MII cells not only increased the tumor initiation capacities of our cells when tran-
splanted orthototically in the mouse fat pad (Figure 7 D), but also favoured the 
formation of more malignant, G3-like tumors (Figure 7E and F). Indeed, while 
control MII cells formed small tubular carcinomas displaying no nuclear atypia 
and resembling human G1 tumors (Figure 7E), MII-TAZ(S89A) cells formed in-
vasive less-differentiatied carcinomas that phenocopy several traits of human G3 
breast cancers, such as lack of tubular structures, high nuclear pleomorphism, and 
prominent nucleoli (Figure 7F). Thus, gain of TAZ in MII promotes self-renewal, 
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tumorigenic potential and the acquisition of more malignant phenotype, all hal-
lmark of CSCs.  
 
DISCUSSION 
One of the most important features of neoplasia is the ability to evolve, so that 
tumors progressively loose the histological characters of the tissues from which 
they arise and acquire an architecture that resembles less differentiated states of 
normal tissues (Egeblad et al., 2010). The knowledge of the differentiation status 
of a tumor plays an important role for deciding the appropriate treatment for a 
cancer patient: low-differentiated cancer cells frequently develop malignant abili-
ties such as invasive behaviours, resistance to chemotherapy and metastatic pro-
clivity. Indeed, pathologists categorize tumors by criteria that include the mor-
phology of cancer cells and the organization of the neoplastic tissue. A point in 
case is represented by breast cancer: breast tumors are classified by a composite 
score, the grade, that integrates assessments of cell de-differentiation and replica-
tive potential. Low-grade breast tumors (G1) are in general benign, while high 
grade breast cancers (G3) are prone to recur in the primary tumor site after sur-
gery or chemotherapeutic treatment, and to metastatize to distant organs (Elston, 
1991). Despite the importance of histological grading for the prognosis of breast 
cancers, the cellular and molecular basis for the differences between G1 and G3 
tumors is poorly understood. 
Here we found that TAZ recapitulates some salient traits that have been pre-
viously associated with CSCs. The molecular signature of TAZ and its protein le-
vel are tightly linked with progression from well-differentiated to high-grade tu-
mors (Figure 8), during which the CSCs content has been shown to dramatically 
increase (Pece et al., 2010). Indeed, low grade G1 tumors display a low number of 
TAZ-positive cells that greatly increase in G3 cancers, and in this respect TAZ 
can be treated as prognostic marker. Moreover, TAZ activity, which we have 
shown to be associated to molecular signatures of stemness, is a clinical relevant 
tool to predict the proclivity to develop metastasis, that is another hallmark of 
CSC activity. In the most heterogeneous breast tumors, the ones catalogued as G2, 
TAZ activity can distinguish G2 tumors more similar to G1 and those that resem-
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ble G3 cancers, in order to prognostically classify also this intermediate class of 
diseases. 
Characterization of CSC purified from in vitro cell cultures have also demostrated 
an upregulation of the TAZ protein with respect to non-CSCs, that in any case are 
genetically identical. 
At the functional level, by loss of function we demonstrated that TAZ is required 
for self-renewal and for tumor-initiation properties of breast cancer cells of MIV 
cells and also for the maintanance of the CD44
high
 subpopulation in MII cells. 
Raising TAZ level and activity is sufficient for converting otherwise benign expe-
rimental tumors into a more aggressive G3-like histopatological phenotype. Thus, 
TAZ expression and activity embody characteristics that have been classicaly lin-
ked to CSCs in breast tumors, that is, tumor heterogeneity, reduced differentia-
tion, self-renewal potential, immonological phenotype, and tumor-seeding abili-
ties. Moreover, a similar function of TAZ have also emerged in malignant glio-
mas (Bhat et al., 2011).  
An unsettled issue in the cancer stem cell field is whether the potential of self-
renewal is an exclusive property of CSCs, or whether plasticity exists in these hi-
erarchical lineages, such that any cell, even a non-CSC, could acquire self-
renewal potential under appropriate intrinsic or extrinsic cues (Chaffer et al., 
2011b; Gupta et al., 2009). Interestingly, this type of plasticity has been recently 
demonstrated in mammary epithelial cells, where, in a seemingly stochastic man-
ner, non-CSCs and even non-transformed cells, could be spontaneously reverted 
to a stem-like state without genetic manipulations (Chaffer et al., 2011). Here we 
showed a similar type of transition but in a molecularly controlled manner, as 
conditional activation of TAZ in putative non-CSCs could reactivate their self-
renewal potential. Thus, in breast cancer, TAZ levels appear to regulate pheno-
typic plasticity in both the prospetictive stem and non-stem compartments.  
Control of proliferation and self-renewal are clearly related events in CSC 
biology and YAP and TAZ have been previously described both as oncogenes and 
tumor suppressors (Pan, 2010). It is worth noting, however, that the link between 
TAZ and CSC traits appears to be independent of regulation of proliferative ca-
pacity, as TAZ levels do not significantly impact on proliferation of 2D cultures 
or mammospheres growth. That said, proliferation may require a threshold of 
TAZ (or of combined YAP/TAZ) lower than that one required for self-renewal. 
 26 
 
A mechanism that links cell polarity and TAZ in breast cancer cells 
We also investigated the mechanism that induce TAZ stabilization in CSCs. This 
is extensively treated in the PhD thesis of Dr. Francesca Zanconato. 
Epithelial-to-Mesenchymal Transition (EMT) (Thiery et al., 2009) has been 
shown to endow stem-cell properties (Mani et al., 2008) and we demonstrated that 
EMT induces TAZ, and that TAZ is required for EMT-induced self-renewal. As 
EMT entails loss of cell polarity, we found that a critical event for TAZ activation 
is deregulation of the cell polarity determinant Scribble. Scribble is also fre-
quently disabled during mammary tumorigenesis (Zhan et al., 2008); it also serves 
as tumor suppressor in Drosophila (Humbert et al., 2008) and participates in 
Hippo signaling (Skouloudaki et al., 2009). Biochemically, TAZ and Scribble 
form a complex at endogenous protein levels in nontransformed and tumoral 
mammary epithelial cells. Remarkably, loss-of-Scribble - or EMT - disrupts the 
association of TAZ with the core Hippo kinases and prevent inhibitory 
phosphorylation and association of TAZ to !-TrCP. 
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PART 2 
 
Wnt signaling pathway has prominent and widespread roles in develop-
ment, tissue homeostasis and cancer (Moon et al., 2004; Clevers, 2006; Mac-
Donald et al., 2009). For example, Wnts coordinate proliferation and differentia-
tion during organ growth, and serve as extrinsic factors to regulate stem cells for 
tissue maintenance and regeneration (Clevers, 2006; Niehrs and Acebron, 2012). 
A key step in this pathway is the regulation of cytosolic !-catenin levels (Mac-
Donald et al., 2009) by a dedicated “destruction” complex. This complex consists 
of core components: the scaffold proteins Axin and adenomatous polyposis coli 
(APC) and the glycogen synthase kinase-3 (GSK3). Mutations in components of 
the !-catenin destruction complex (mainly APC) result in cancer, most notably of 
the colon (Clevers, 2006).  
In cells not experiencing Wnt signaling (Figure 14A, left panel), the pool 
of cytosolic free !-catenin is efficiently captured by the destruction complex and 
phosphorylated by CK1 at S45, which in turn primes GSK3 phosphorylation of !-
catenin on the N-terminal T41, S37 and S33 residues (Liu et al., 2002). This 
phosphomotif, called phosphodegron, is recognized by the F-box-containing pro-
tein !-TrCP ubiquitin E3 ligase and targeted to ubiquitination and proteasomal 
degradation (Aberle et al., 1997; Kitagawa et al., 1999).  
Wnt ligands are a large family of secreted glycoproteins. They bind the frizzled 
(FZD) and low-density-lipoprotein-related protein 5/6 (LRP5/6) coreceptor com-
plex to activate the canonical Wnt signaling pathway. Through an incompletely 
resolved mechanism, the activated receptor complex disrupts or functionally inac-
tivates the destruction complex, leading to the accumulation and nuclear translo-
cation of !-catenin (Figure 14A, right panel). Several models have been proposed 
to follow Wnt receptor activation and as a consequence to cause !-catenin stabili-
zation (reviewed in Li et al., 2012). These include: sequestration of Axin by LRP 
receptors, degradation of Axin, inactivation/desruption of the destruction complex 
by Dishevelled, inhibition of GSK3 kinase activity, dephosphorylation of !-
catenin, sequestration of GSK3 into multivescicular bodies (Taelman et al., 2010), 
dissociation of !-TrCP from !-catenin (Li et al., 2012). In the nucleus, !-catenin 
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engages mainly T-cell factor (TCF)/LEF transcription factors to activate the Wnt 
transcriptional program. In order to monitor Wnt pathway activation, several labo-
ratories have built reporter constructs containing multimerized TCF binding sites 
(reviewd in Barolo, 2006), to be used both in cell and in vivo. However, these re-
porters should be used with careful attention, as they often give different respon-
ses and, more importantly, they do not respond to other modalities by which Wnt 
activate gene transcription (Barolo, 2006). 
Independently of Wnt signaling, the transcriptional co-activators TAZ and 
YAP have recently emerged at the centerpiece of poorly-understood mechanisms 
that control tissue growth and organ size (Pan, 2010). TAZ and YAP promote cell 
proliferation and inhibit differentiation, particularly in stem cells and organ-
specific progenitors, and therefore their activity must be finely tuned in order to 
avoid loss of tissue regeneration and, at the other extreme, overgrowth and emer-
gence of tumors (Ramos and Camargo, 2012).  
Interestingly, there are - at least superficially - clear elements of overlap between 
!-catenin and TAZ or YAP: biochemically, all are short lived proteins in the cy-
toplasm, as they are degraded by the same !-TrCP ubiquitin ligase complex (Liu 
et al., 2010; MacDonald et al., 2009; Zhao et al., 2010); biologically, they appear 
to control overlapping processes in a number of epithelial and non-epithelial con-
texts. Although this hints at some form of joined regulation, the possibility that 
Wnt could signal through TAZ or YAP stabilization has not been explored. 
 
RESULTS 
TAZ is activated by Wnt signaling 
We initiated this study by discovering that treatment of HEK293 cells with 
Wnt3A triggered a remarkable increase of TAZ protein levels (Figure 9A), without 
affecting TAZ transcript levels (Figure 9B). This suggested that Wnt3A promoted 
TAZ protein stabilization. As control, Wnt3A activated also !-catenin and !-
catenin-dependent transcription (Figure 9C). Importantly, Wnt3A triggered a ro-
bust induction of transfected 8xGTIIC-Lux  (Figure 9A, compare lanes 1 and 2), a 
synthetic luciferase sensor containing multimerized responsive elements of TE-
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AD, the main DNA-binding cofactor of TAZ (Dupont et al., 2011). This induc-
tion was dependent on specific stabilization of TAZ, as revealed by depletion of 
endogenous TAZ by siRNA (Figure 9A, lane 4),. However, this was not depen-
dent on !-catenin or !-catenin target genes, as !-catenin loss after Wnt3A 
treatment does not modify TAZ induction  (Figure 9D). Taken together, these da-
ta suggested that Wnt signaling stabilizes and activates TAZ. 
We next asked whether Wnt regulated TAZ through the canonical GSK3-APC-
Axin intracellular pathway that controls !-catenin (MacDonald et al., 2009). We 
therefore reactivated the !-catenin destruction complex in Wnt-treated cells by u-
sing XAV939: this small molecule promotes Axin stabilization by inhibiting the 
poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2 that otherwise would 
triggered Axin to degradation (Huang et al., 2009). As reported for !-catenin, 
XAV939 inhibited the effects of Wnt3A on TAZ transcriptional activity and sta-
bility (Figure 9A, lane 3). Conversely, inactivation of Axin, GSK3 or APC by 
transfections of corresponding siRNAs induced TAZ stabilization and activity 
(Figure 9E), phenocopying Wnt stimulation. As a control, these treatments pro-
moted also !-catenin dependent-transcription (Figure 9F).  Thus, Wnt signaling 
regulates TAZ in a way that depends on !-catenin multi-subunit destruction 
complex. 
We also tested the possibility that Wnt might activate TAZ by inhibiting the 
Hippo kinase cascade. Indeed, according to the classical “Hippo” view, TAZ 
should get phosphorylated and inactivated by its upstream kinase, LATS1/2. As 
shown in Figure 9G, treatment with Wnt3A ligand could still induce TAZ in 
LATS1/2 depleted cells, indicating that LATS activity is not crucial for TAZ 
regulation by Wnt. We also expressed in HEK239 cells a phosphomutant TAZ 
protein lacking all LATS phosphorylation sites (TAZ 4SA, in which Serines 66, 
89, 117 and 306 have been mutated to Alanines): TAZ 4SA is, as expected, more 
stable than wild-type TAZ; yet, it remains sensitive to Wnt regulation (Figure 
9H), thus concluding that Wnt pathway activates TAZ independently of the Hippo 
cascade. 
To extend our findings to in vivo conditions, we obtained Ah-Cre; Apcfl/fl mice in 
which the induction of the Cre recombinase can be achieved in liver, gut and other 
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organs by intraperitoneal injection of the drug !-naphtophlavone (Sansom et al., 
2004). In this context, we verified that in livers of conditional Apc knock-out mice 
TAZ protein level and activity were increased with respect to control mice, as 
measured by the induction of two well-established TAZ targets Cyr61 and CTGF 
(Figures 9I-K). As control, Apc deletion upregulates also !-catenin target Cyclin-
D1 (Figure 9L). 
 
Role of GSK3 in TAZ degradation 
Next, we sought to determine by which mechanism Wnt signaling promotes TAZ 
stability and activity. We tested the hypothesis that TAZ might follow the same 
steps of !-catenin on its route to degradation in the context of the Wnt cascade. 
Indeed, there are element of overlap between the biochemical regulation of TAZ 
and !-catenin. As reported, !-TrCP is important, in the Wnt OFF status, for the 
degradation of both !-catenin and TAZ. This was further confirmed by the fact 
that !-TrCP inactivation, either by siRNA transfection or interference with a 
dominant negative form of Cullin1 (an essential adaptor of the !-TrCP E3 ubiq-
uitin ligase complex), stabilized TAZ protein level in both MII (Figure 10A) and 
HEK293 (Figure 10B) cells. 
In the canonical Wnt-OFF view, the recognition and successive degrada-
tion of !-catenin by !-TrCP (Aberle et al., 1997; Kitagawa et al., 1999) occurs 
upon phosphorylation by GSK3 (MacDonald et al., 2009; see Figure 14). We 
therefore tested the possibility that GSK3 phosphorylation and !-TrCP recogni-
tion might also drive TAZ degradation. First, endogenous !-TrCP failed to asso-
ciate to TAZ in co-immunoprecipitation assays from lysates of GSK3-depleted 
MII cells (Figure 10C), indicating that TAZ/!-TrCP interaction requires GSK3 or 
a GSK3-mediated modification. Moreover, in reconstitution experiments, we 
found that GSK3 kinase activity was essential for TAZ degradation: indeed, 
knockdown of GSK3 stabilized TAZ in MII cells (Figure 10D, lanes 1 vs. 2 and 4 
vs. 5) and reconstitution with wild-type GSK3 (Figure 10D, lane 3), but not with 
kinase-dead GSK3 (Figure 10D, lane 6), rescued TAZ levels and activity. This 
was also confirmed in HEK293 cells (Figure 10E).  
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TAZ has consensus sites (Serines 58 and 62) for GSK3 phoshporylation on a 
DSGXXS motif, called “phosphodegron” (Figure 10F), that tags a given protein 
for !-TrCP recognition, ubiquitination and proteosomal degradation, as in the case 
of other Wnt-regulated proteins, !-catenin being the prototypical example (Kim et 
al., 2009; Taelman et al., 2010). This raised the simple possibility that, in analogy 
to !-catenin, GSK3 might promote TAZ degradation by phosphorylating these 
two sites in the context of the Wnt cascade. Thus, if GSK3 directly phosphory-
lates TAZ, mutation of these two putative GSK3-target sites from Serine to 
Alanine should render TAZ resistant to GSK3-mediated degradation and insensi-
tive to Wnt stimulation. However, in stark contrast with this prediction, the stabil-
ity of TAZ S58/62A was still sensitive to GSK3 inhibition (Figure 10G) and the 
activity of TAZ S58/62A could still be induced by Wnt3A (Figure 10H). We then 
conclude that GSK3 keeps TAZ levels low irrespectively of the integrity of these 
N-terminal TAZ motif. 
 
Role of !-catenin in TAZ degradation 
As a mechanism entailing direct GSK3 phosphorylation of TAZ was unlikely, we 
considered that the effect of GSK3 on TAZ stability was primarily indirect, that 
is, through modification of an intermediary protein. According to our hypothesis, 
this intermediary protein has to: i) interact with TAZ; ii) be phosphorylated by 
GSK3 and, as such, serve as adaptor for !-TrCP-mediated TAZ degradation; iii) 
activate TAZ when absent. In the context of Wnt signaling, we demonstrated that 
the most likely culprit protein was !-catenin itself, which was proved to fulfill all 
the previous requirements (Figure 11). Indeed, by co-immunoprecipitation ex-
periments, !-catenin and TAZ form a complex at endogenous protein levels (Fig-
ures 11A and B). Furthermore, depletion of !-catenin by siRNA revealed that !-
catenin was required for the endogenous association of TAZ to !-TrCP in MII 
cells  (Figure 11C). In this scenario, by impairing TAZ/!-TrCP interation, the ab-
sence of !-catenin should stabilize/activate TAZ. This was confirmed by knock-
down experiments of !-catenin that caused a robust stabilization of TAZ protein, 
induction of TAZ transcriptional activity and TAZ nuclear accumulation (Figures 
11D-F). We excluded the possibility that loss of !-catenin was affecting TAZ by 
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regulating events related to the Hippo pathway (Cordenonsi et al., 2011), because 
it does not modify the apico-basal polarity (Scribble localization, Figure 11F), the 
cadherin adherens junctions (Figure 11F), or the levels of active LATS (Figure 
11G). 
All these experiments bring us to elucidate an interesting scenario for TAZ 
regulation in the Wnt-OFF world: that is, GSK3 prompts TAZ degradation by 
modifying/phosphorylating !-catenin and, as consequence, GSK3-modified !-
catenin brings TAZ to !-TrCP-mediated degradation. So, is it the GSK3-
phosphorylated pool of !-catenin the ultimate mediator of TAZ degradation? For 
this, we analyzed TAZ stability and CTGF induction in two MII cell lines, de-
pleted of endogenous !-catenin and reconstituted at near-to-endogenous levels 
with either wild-type !-catenin or a S/A phospho-mutant !-catenin (Figure 11H). 
This !-catenin mutant harbors N-terminal point-mutations that prevent GSK3 
phosphorylation and !-TrCP recognition (Liu et al., 2002). As above, knockdown 
of !-catenin promoted TAZ stabilization in both MII derivatives (Figure 11H, 
lanes 1 and 2, and lanes 4 and 5); adding back wild-type !-catenin rescued TAZ 
degradation (Figure 11H, lane 3). However, reconstitution with S/A phospho-
mutant !-catenin had no effect (Figure 11H, lane 6), indicating that TAZ degrada-
tion relies on !-catenin phosphorylation by GSK3. In these experiments, changes 
in TAZ protein levels were consistently paralleled by changes in its activity, as 
indicated by the expression of its target CTGF (Figure 11H). 
Further support to this view was provided by experiments in HepG2 hepa-
tocarcinoma cells. These cells carry two different !-catenin alleles: one encoding 
wild-type !-catenin and the other encoding a constitutively active !-catenin bear-
ing a natural deletion in the N-terminus encompassing the GSK3 phosphorylation 
sites (Figure 11I). We used a siRNA oligonucleotide (#4) that specifically binds 
within the deletion and, as such, only targets the wild-type and not the mutated al-
lele. By using this siRNA, we found that the sole wild-type !-catenin, able to be 
phosphorylted by GSK3, is responsible for TAZ degradation (Figure 11J, com-
pare lanes 1 and 5) as depletion of both isoforms does not further increase TAZ 
stability (Figure 11J, compare lanes 1, 3 and 5).  
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Mapping the interaction between TAZ and !-catenin 
Since we have established a new role for !-catenin in the Wnt-OFF world, as 
adaptor for bridging TAZ to the !-TrCP complex, we wanted to map the TAZ 
domain(s) that is necessary for !-catenin binding and next verified that a TAZ 
mutant that cannot interact with !-catenin should not bind !-TrCP. For this, we 
obtained GST-TAZ deletion constructs (Figure 12A), that we expressed in bacte-
ria as recombinant proteins, and in vitro-translated 
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S-radiolabeled !-catenin. 
Next, by GST-pulldown, we identified the “WW” domain of TAZ as necessary 
for the association to in vitro-translated !-catenin (Figure 12B). Once expressed in 
human cells not experiencing Wnt signaling, TAZ deleted of the WW domain 
(TAZ 'WW) was more stable and basally more active than wild-type TAZ (Fig-
ures 12C and E). Importantly, TAZ 'WW was incapable to associate to endoge-
nous !-catenin and !-TrCP (Figure 12D). As such, TAZ 'WW could not be fur-
ther stabilized nor activated by Wnt stimulation in HEK293 cells (Figure 12E). 
Critically, the behavior of TAZ 'WW could not be ascribed to an escape from the 
Hippo pathway, as TAZ 'WW is still phosphorylated on the leading LATS target 
S306 (Figure 12F) and can be further stabilized by LATS1/2 depletion (Figure 
12G). This corroborates the independence of the two regulation of TAZ: one by 
Wnt/!-catenin, and the other by the Hippo pathway. 
 
"-catenin participates to TAZ regulation 
"-catenin is a homologue of !-catenin, and the two proteins are thought to operate 
in an overlapping manner in several contexts: they have redundant functions in 
cell adhesion and share Wnt-dependent regulation through phosphorylation by 
GSK3 and !-TrCP-mediated degradation (Xu et al., 2009). Importantly, TAZ as-
sociates with "-catenin at endogenous protein levels (Figure A), and, similarly to 
!-catenin, this interaction is dependent on the integrity of the TAZ WW domain 
(Figure 13B). This prompted us to test if "-catenin also shares with !-catenin the 
capacity to regulate TAZ.  To examine this, we monitored TAZ activity in 
HEK293 cells transfected with siRNAs against !-catenin, "-catenin or both. De-
pletion of "-catenin led to TAZ stabilization (Figure 13C) and TAZ-dependent 
transcriptional activity (Figures 13D and E). Interestingly, concomitant depletion 
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of both !- and "-catenin resulted in even stronger transcriptional activation (Fig-
ure 13D and E). This indicates that these factors play independent and additive 
roles in TAZ inhibition. 
 
DISCUSSION 
Inhibition of the !-catenin destruction complex is central to Wnt signaling; 
this results in !-catenin stabilization, the last biochemical event of the Wnt cas-
cade. Here we reveal the existence of a new downstream function of !-catenin, in 
regulating the stability of another potent transcriptional co-activator, TAZ (Figure 
14). 
 
TAZ as a downstream mediator of Wnt signaling 
The results shed new light on the modalities by which the Wnt pathway controls 
gene expression, not only through the !-catenin/TCF complex, but also through 
TAZ, which came out as general feature of the Wnt response in a variety of cellu-
lar model systems. It is noteworthy that when we challenged by gene expression 
profiling the relevance of TAZ downstream of Wnt signaling, the regulation of a 
very significant fraction of Wnt target genes turned out to be TAZ-dependent both 
in mammary epithelial cells and colorectal cancer cells (PhD Thesis of Dr. Fran-
cesca Zanconato). The specific relevance of !-catenin or TAZ responses will li-
kely depend on the cellular con-text. In some cell types, or experimental condi-
tions, the effects of Wnt may primarily depend on TCF-dependent transcription; 
for example it is possible that mouse embryonic stem (ES) cells may represent 
one extreme situation, whereby TCF3/!-catenin interaction is central for self-
renewal, whereas TAZ stabilization is irrelevant (Varelas et al., 2008). Makita et 
al., reported that a minor fraction of TAZ mutant mice develop to term, sugge-
sting that TAZ may primarily contribute to Wnt responses in adult tissues. It must 
be also noticed, however, that the vast ma-jority of TAZ mutants die in utero with 
an as yet uncharacterized phenotype (Makita et al., 2008); in fact, we have been 
unable to obtain any TAZ
-/-
 newborn in our colony (unpublished data). This leaves 
open the potential of an overlap between Wnt and TAZ also in embryonic develo-
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pment, perhaps consistently with the phenotype of TAZ-deficient zebrafish em-
bryos that display severe defects in mesodermal derivatives, including massive 
loss of bone differentiation (Hong et al., 2005). 
  
A new role for !-catenin 
!-catenin plays active roles both in the presence and absence of Wnt ligands (Fi-
gure 14). In the absence of Wnt signaling (i.e., Wnt OFF state), the pool of pho-
spho-!-catenin is an essential element for continuous TAZ degradation as it serves 
as critical scaffold for TAZ recognition by the !-TrCP E3 ubiquitin ligase. This 
configures an unexpected role for cytoplasmic !-catenin: besides being re-cruited 
to the destruction complex for its own degradation, !-catenin works as yet another 
intermediary of the Wnt cascade upstream of TAZ. Much evidence support this 
conclusion, including: 1) TAZ and !-catenin form a complex at endogenous pro-
tein levels in unstimulated cells (TAZ/!-catenin interaction was already reported 
by Imajo et al., 2012); 2) !-catenin phosphorylation is required for TAZ degrada-
tion; 3) depletion of both GSK3 and !-catenin impairs TAZ/!-TrCP interaction 
and has the same effects on TAZ. 
One possible interpretation of these results would be that TAZ could only bind the 
phosphorylated form of !-catenin. However, TAZ and !-catenin proteins can as-
sociate in vitro (Figure 12B), arguing against a strict requirement of !-catenin 
phosphorylation. Another equally plausible interpretation is that, irrespectively of 
!-catenin phosphorylation, TAZ may effectively associate to !-catenin only after 
cytoplasmic !-catenin is captured by the destruction complex, a scenario compati-
ble with other proteins of the destruction complex either reinforcing the !-
catenin/TAZ interaction or escorting the !-catenin/TAZ/!-TrCP recognition. Cle-
arly, the structural and thermodynamic details by which !-catenin recognizes TAZ 
and favors its association with !-TrCP remains ground for future investigations. 
Moreover, the relevance of !-catenin as endogenous inhibitor of TAZ was valida-
ted at the genome-wide level in mammary epithelial cells by microarray experi-
ments (PhD Thesis of Dr. Francesca Zanconato). 
"-catenin represents yet another variation on this scenario: this !-catenin-related 
protein is regulated by the Wnt/GSK3/!-TrCP axis but its relevance for TCF-
dependent transcription is still debated (Ben-Ze'ev, 1999). Nevertheless, here we 
show that "-catenin is able to regulate TAZ-dependent transcriptional responses 
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by promoting TAZ instability in concert, or redundantly, with !-catenin. From 
this “TAZ perspective”, "-catenin may effectively be part of the Wnt response. 
We propose that in cells experiencing Wnt activity, !-catenin, per se largely dis-
sociated from !-TrCP, is incapable to carry out any adaptor function for TAZ, and 
as such is irrelevant for TAZ regulation (Figure 14). In this view, it is the loss of 
the association of phospho-!-catenin to !-TrCP that causes TAZ stabilization: we 
found that TAZ is indeed stabilized not only by Wnt signaling, but also by expe-
rimentally removing !-catenin from cells lacking Wnt stimulation. It also follows 
that removing !-catenin from cells where the fraction of phospho-!-catenin is ne-
gligible - such as Wnt treated cells - should be inconsequential for TAZ function 
and not lead to further stabilization of TAZ. In fact, !-catenin knock-down cannot 
further increase TAZ-dependent transcription in Wnt-stimulated HEK293 cells 
(Figure 1D, lane 3). 
The functions of the two pools of !-catenin could be visualized at the endogenous 
level and within the same cellular context by using HepG2 cells, containing both 
wild-type and a non-phosphorylatable mutant !-catenin. In line with our model, 
only wild type !-catenin is relevant to oppose TAZ; mutant-!-catenin is unable to 
bring TAZ to degradation, while it mediates the !-catenin/TCF transcriptional re-
sponses. 
 
TAZ stability at the crossroad between Wnt and Hippo signaling.  
Cell-cell adhesion and polarity cues activate the Hippo/LATS kinases leading to 
TAZ phosphorylation and sequestration in the cytoplasm (Pan, 2010). Moreover, 
a largely LATS-independent modality to regulate TAZ stability and activity has 
been also shown to occur as consequence of changes in cell shape and cytoskele-
tal reorganization induced by mechanical cues, such as rigidity of the extracellular 
matrix (Dupont et al., 2011). Here we further expanded the land-scape of TAZ re-
gulation by showing that TAZ is controlled by a major family of secreted growth 
factors, in a manner largely independent from Hippo signaling. 
One point worth discussing is that TAZ is phosphorylated by LATS and CK1 to 
generate a C-terminal phosphodegron, that has been shown to be relevant for TAZ 
stability and to promote direct association to !-TrCP, at least under conditions of 
protein overexpression (Liu et al., 2010). This is apparently at odd with the pre-
sent findings indicating that, at endogenous protein levels, TAZ and !-TrCP asso-
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ciate indirectly through a !-catenin bridge. In fact, these two scenarios are per-
fectly compatible, as these represent formally independent modalities of regula-
ting TAZ stability by the Hippo and Wnt cascades, respectively. Indeed, here we 
show that LATS inhibition or mutation of the LATS or CK1 phosphorylation sites 
are irrelevant for TAZ regulation by Wnt (Figure C-D and data not shown); con-
versely, a TAZ mutant unable to bind !-catenin is insensitive to Wnt but remains 
under LATS1/2 control. Taken together, these findings open very intriguing pos-
si-bilities for TAZ as hub integrating different physiological inputs. 
This network accommodates self-regulating feedback loops; TAZ was demonstra-
ted to negatively regulate the Wnt pathway by inhibiting Dishevelled, a positive 
Wnt regulator (Varelas et al., 2010a). This may provide a ceiling to the levels of 
TAZ activation by Wnts and a mechanism to turn off TAZ-dependent responses. 
Finally, having established TAZ as Wnt effector opens up many therapeutic pos-
sibilities. Targeting TAZ could curb aberrant Wnt signaling in a variety of cancers 
and other disorders. Conversely, targeting the Wnt pathway by restoring the inte-
grity of the destruction complex would effectively inhibit, at once, two of the 
most potent oncogenic drivers of human malignancies. 
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EXPERIMENTAL PROCEDURES 
 
Reagents and plasmids 
Doxorubicin, Paclitaxel, XAV939 and !-naphthoflavone were from Sigma. Doxy-
clycine was from Calbiochem.  
The constructs for shControl and shTAZ expression in MIV cells were prepared 
by cloning the Control and TAZ#2 sequences (see RNAi section) into pLKO.1-
puro lentiviral vector (Addgene #8453; Stewart et al., 2003) according to manu-
facturer’s protocol.  
pSUPER-RETRO-PURO vectors containing the shGFP or TAZ RNAi sequences 
were used for stable knockdown in MII. 
For stable expression of TAZ variants, TAZ cDNAs were subcloned from pEF-
TAZ-N-Flag and pEF-TAZ-N-Flag(S89A) constructs (Addgene #19025 and 
#19026, Kanai et al., 2000) to pBABEhygro (Addgene #1765). The retroviral 
constructs coding for Flag-mTAZ S58/62A, Flag-mTAZ S306A, Flag-mTAZ 
S306/309A and Flag-mTAZ !WW (deleted of residues 111-158) were generated 
by mutagenesis from pBABEhygro mTAZ wt. Flag-mTAZ 4SA (i.e, 
S66/89/117/306A) was as in Dupont et al. (2011). All TAZ cDNA sequences we-
re also subcloned in pCS2 for transient expression in HEK293 cells. For GST-pull 
down experiments wild-type full-length mouse TAZ was cloned in pGEX4T1; 
from this deletion constructs of GST-TAZ were generated by enzymatic digestion 
and self-ligation. Mouse TAZ cDNA is insensitive to the siRNAs used to target 
the human transcript. 
Doxycycline-inducible lentiviral constructs were obtained by substituting the 
Oct4 sequence in FUW-tetO-hOCT4 (Addgene #20726; Hockemeyer et al., 2008) 
with mTAZ wt or S89A cDNAs (see above) or with EGFP sequence from PL-
SIN-EOS-C(3+)-EiP plasmid (Addgene #21313, Hotta et al., 2009). In this type of 
experiments cells were also co-transduced with FUdeltaGW-rtTA (Addgene 
#19780, Maherali et al., 2008). This strategy was implicated for cells used in Fig-
ures 3H-I and 5D-E.  
A doxycycline-inducible retroviral vectors-based strategy was implicated for cells 
used in Figures 10D and 11H. Human myc-tagged GSK3" wt or kinase-dead 
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(KD) mutant (K85A) cDNAs were subcloned in pCS2 and made insensitive to 
GSK3" siRNA#1 by introducing silent mutations within the siRNA targeting se-
quence by PCR. For inducible expression of GSK3" in MII cells (Figure 10D), 
siRNA-insensitive GSK3" variants were subcloned in a doxycycline-inducible re-
troviral expression vector (pSTC-Puro), and retroviral particles were used to in-
fect MII cells previously transduced with pBABEhygro rtTA (MII-rtTA cells). 
cDNAs for human "-catenin, wild-type and phospho-mutant (S/A = S33/37/41A, 
corresponding to the GSK3 sites and the CK1 priming site S45A), were subcloned 
in pCSP1 and were made insensitive to "-catenin siRNA#4 by introducing silent 
mutations within the siRNA targeting sequence by PCR. For inducible expression 
of "-catenin in MII cells (Figure 11H), both siRNA-insensitive "-catenin variants 
were subcloned in pSTC-Puro, and retroviral particles were used to transduce 
MII-rtTA cells. 
pcDNA3-DN-hCUL1-FLAG (#15818) was purchased from Addgene (Jin et al., 
2005). 
All constructs were confirmed by sequencing. 
 
Cell lines 
MII and MIV cells were a gift from S. Santner (Santner et al., 2001). MII cells 
were cultured in DMEM/F12 (Gibco, Life Technologies) with 5% horse serum 
(HS), glutamine and antibiotics, freshly supplemented with insulin, EGF, hydro-
cortisone, and cholera toxin. For all experiments, MII were grown for 2 days at 
high density. MIV and MDA-MB-231 were cultured in DMEM/F12 with 10% 
FBS, glutamine and antibiotics. 
HEK293 cells, Control-L-cells (ATCC #CRL-2648) and Wnt3a-L-cells (ATCC 
#CRL-2647) were cultured in DMEM (Gibco, Life Technologies) supplemented 
with 10% fetal bovine serum (FBS), glutamine and antibiotics. Conditioned media 
from L-cells were harvested according to the ATCC protocol. 
HepG2 cells were cultured in MEM (Gibco, Life Technologies) supplemented 
with 10% FBS, glutamine, antibiotics and non essential aminoacids.  
 
RNA interference 
siRNA transfections were done with Lipofectamine RNAi-MAX (Life technolo-
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gies) in antibiotics-free medium according to manufacturer instructions. Se-
quences of siRNAs are provided in Table 3. 
For stable knock-down, both lentiviral or retroviral vectors were used. Lentiviral 
particles were prepared by transiently transfecting HEK293T cells with lentiviral 
vectors together with packaging vectors (pMD2-VSVG and psPAX2). Retroviral 
particles were prepared by transiently transfecting HEK293GP cells with retrovi-
ral vectors together with an envelope-producing vector (pMD2-Env). Infections 
were carried out as in Martello et al. (2010). 
 
Western blot 
Cells were harvested by sonication and extracts quantified with Bradford method.  
Proteins were run in 4-12% Nupage MOPS acrylamide gels and transferred onto 
PVDF membrans by wet electrophoretic transfer. Blots were blocked with non-fat 
dry milk and incubated overnight at 4°C with primary antibodies. Secondary anti-
bodies were incubated 1 hr at room temperature, and then blots were developed 
with chemiluminescent reagents. 
For Western blot: anti-YAP/TAZ, anti-Survivin, anti-GSK3, anti-"-catenin and 
anti-#-catenin monoclonal antibodies and anti-CTGF and anti-Cyr61 polyclonal 
antibodies were from Santa Cruz. anti-GAPDH monoclonal antibody was from 
Millipore. Anti-PAI1 was from BD Biosciences. Anti-"-TrCP, anti-LATS1 and 
anti-phospho-S909 LATS1 polyclonal antibodies were from Cell Signaling, and 
anti-"-catenin polyclonal antibody was from Sigma. Anti-phospho-S306 TAZ 
polyclonal antiserum was obtained from one rabbit (out of two) immunized with a 
synthetic peptide (Covance). 
 
Collection and Processing of Breast Cancer Gene-Expression Data  
We started from a collection of 7 datasets (Table 1) containing microarray data of 
breast cancer samples annotated with histological tumor grade and clinical outco-
me. All data were measured on Affymetrix HG-U133A arrays and have been do-
wnloaded from NCBI Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/). 
Since raw data (.CEL files) were available for all samples, expression values of 
the metadataset were generated from fluorescence signals using the robust mul-
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tiarray average procedure (RMA, Irizarry et al., 2003). Specifically, intensity le-
vels have been background adjusted, normalized using quantile normalization, 
and log2 expression values calculated using median polish summarization. 
To identify genes upregulated in histological G3, we compared the expression 
profiles of G3 versus G1 samples using SAM algorithm coded in the samr R 
package (Tusher et al., 2001). In SAM, we estimated the percentage of false posi-
tive predictions with 1000 permutations and set the q-value threshold at 1x10-
3
. 
The comparison between 270 G3 and 182 G1 samples of the metadataset enlisted 
78 Affymetrix probesets overexpressed more than two times in G3 cancers. 
As signaling pathway signatures we used lists of genes activated by signaling pa-
thway components in normal, immortalized or tumor human mammary cells. The-
se signatures are TAZ/YAP (Zhang et al., 2009a), Notch A (Notch signature in 
Mazzone et al., 2010), Notch B (NICD signature in Mazzone et al., 2010), RAS 
(Bild et al., 2006), ERBB2 (Mackay et al., 2003), "-catenin (Bild et al., 2006), 
Wnt (DiMeo et al., 2009), TGF-"-A (Padua et al., 2008), TGF-"-B (Adorno et al., 
2009), NF-kB (Park et al., 2007), STAT3 (Alvarez et al., 2005), and Src (Bild et 
al., 2006). The YAP conserved signature (listed in Cordenonsi et al., 2011) is 
composed of a selection of genes that have been found activated by YAP overe-
xpression in human mammary cells (MCF10A) (Zhao et al., 2008) and that are al-
so activated upon YAP overexpression in mouse liver tissues (Dong et al., 2007) 
or in immortalized mouse fibroblasts (Ota et al., 2008). Thus, this signature repre-
sents a list of evolutionary conserved YAP target genes. We used the following 
stem cell signatures: human normal mammary stem cells (hNMSC; Pece et al., 
2010), invasiveness gene signature (IGS; Liu et al., 2007), CD44high (Shipitsin et 
al., 2007), embryonic stem cells 1 (ES1) and embryonic stem cells 2 (ES2) (Ben-
Porath et al., 2008), and embryonic stem cells-like (ES-like, Kim et al., 2010). All 
biostatistical analyses were performed in collaboration with prof. Silvio Bicciato. 
 
Mammosphere assay 
Cells were trypsinized, counted, and plated as single-cell suspensions (1000 
cells/cm
2
) on ultra-low attachment plates (Costar). Mammospheres were counted 
after 5 days; cells were thereafter dissociated to be reseeded for a second round of 
mammosphere formation. Mammosphere cultures of MII and their derivatives 
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were performed as described in Dontu et al. (2003); for MIV cells, culture condi-
tions were as in Ponti et al. (2005). Statistical analyses were done with Prism sof-
tware (GraphPad).  
 
Tumorigenesis Assays  
For xenograft tumor-seeding studies, the indicated numbers of MII or MIV cells 
were suspended in 100 µl Matrigel (BD Biosciences) and injected in the fat pads 
of immunocompromized female mice. Tumor formation was assayed by palpa-
tion. After the indicated periods, mice were sacrificed and tumors were explanted 
for histological analyses. Tumorigenesis assays were performed in collaboration 
with prof. Antonio Rosato. 
 
Fluorescence-activated cell sorting 
Cells were detached from plates with TrypLE (Invitrogen), resuspended (5x10
5
 
cells/ml), incubated in running buffer (PBS 13, BSA 0.5%, and EDTA 5 mM) 
with anti-human CD44 (clone G44-26, FITC-conjugated, BD Biosciences) and 
anti-human CD24 (clone ML5, PE-conjugated, BD Biosciences), and finally anal-
yzed or sorted with MoFlo XDP sorter (Beckman Coulter). FACS experiments 
were performed in collaboration with Dr. Chiara Frasson, in the group of prof. 
Giuseppe Basso. 
 
Hoechst Staining for Side Population Identification  
Cells were detached from plates with TrypLE (Invitrogen), resuspended at 1x10
6
 
cells/ml in staining medium containg 5 mg/ml Hoechst-33342 (Molecular Probes) 
and incubated at 37!C for 1.5 hr in the dark. When indicated, 100 µM Verapamil 
was added to the cell suspension. Cells were then washed with cold HBSS sup-
plemented with 2% FBS, incubated with 2 µg/ml PI (to esclude dead PI-
permeable cells from the following cytofluorimetric analysis), washed again with 
cold HBSS + 2% FBS and resuspended in running buffer. FACS profiles were o-
btained with MoFlo XDP sorter (Beckman Coulter). As optical filters for Hoechst 
blue and red fluorescence, a 424/44 band pass filter and a 660/20 band pass filter 
were used, respectively. 
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Treatments with Chemotherapeutic Drugs  
MII cells (5000/well) were plated in 100 µl per well in 96-well plates. One day af-
ter seeding, Doxorubicin or Paclitaxel were added in four replicates per concentra-
tion for each cell line. Cell viability was measured after 72 hr with the CellTiter96 
AQueous Non-radioactive Assay (Promega).  
 
Clinical Samples and Immunohistochemistry  
Archival formalin-fixed paraffin-embedded breast cancer specimens were collec-
ted at the Istituto Nazionale Tumori (INT) of Milan and at the Ospedale San Bas-
siano-Bassano del Grappa, Italy. For IHC, 4 µm thick sections were obtained from 
tumor samples and were processed for immunohistochemistry. Immunohistoche-
mical staining was performed on formalin-fixed, paraffin-embedded tissue sec-
tions using a fully automated system (Bond-maX; Leica). In brief, one 4-micron-
thick section from each paraffin-embedded block was cut. The sections were de-
paraffinized in Bond Dewax Solution (Leica) at 72!C, rinsed in ethanol, and re-
hydrated in distilled water. Antigen retrieval was performed by heating sections 
for 30 min at 99!C in Bond Epitope Retrieval Solution 1 (Leica). Endogenous pe-
roxidase was blocked by 3% hydrogen peroxide before 30 min of incubation with 
rabbit polyclonal anti-TAZ (Sigma, HPA007415;1:50 diluted). Specimens were 
then washed with phosphate-buffered saline (PBS) and incubated with Bond Pol-
ymer Refine Detection Kit (Leica) according with the manufacturer’s protocols. 
The staining was visualized with 3,30 -diaminobenzidine (DAB) and the slides 
were counterstained with Mayer’s hematoxylin. The sections were then dehydra-
ted, cleared, and mounted. Formalin-fixed, paraffin-embedded positive and nega-
tive controls were included in each run. Tumors were scored as positive when o-
ver 10% of cells displayed nuclear TAZ staining similar or stronger to that of the 
cells of normal ducts included in the same section. Immunohistochemical experi-
ments were performed in collaboration with prof. Anna Parenti. 
 
Luciferase Assays  
Luciferase assays were performed in HEK293 cells with the established 
YAP/TAZ-responsive reporter 8xGTIIC-Lux (Dupont et al., 2011) and with the !-
catenin/TCF-responsive reporter BAT-Lux (Maretto et al., 2003). Luciferase re-
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porters (50 ng/cm
2
) were transfected together with CMV-!-gal (75 ng/cm
2
) to 
normalize for transfection efficiency with CPRG (Roche) colorimetic assay. 
GSK3!, TAZ and DN-Cul1 plasmids were co-transfected at 100, 50 and 100 
ng/cm
2
 respectively. DNA transfections were done with TransitLT1 (Mirus Bio) 
according to manufacturer instructions. DNA content in all samples was kept uni-
form by adding pBluescript plasmid up to 250 ng/cm
2
. For luciferase assays in 
siRNA-depleted cells, cells were first transfected with the indicated siRNAs and, 
after 24 hr, washed from transfection media, transfected with plasmid DNA, and 
harvested 48 hr later. Each sample was transfected in duplicate and each experi-
ment was repeated at least three times independently. 
 
Quantitative Real-Time PCR  
Cells or tissues were harvested in Trizol (Invitrogen) for total RNA extraction, 
and contaminant DNA was removed by DNase treatment. qRT-PCR analyses we-
re carried out on retrotranscribed cDNAs with Rotor-Gene Q (Quiagen) thermal 
cycler and analyzed with Rotor-Gene Analysis6.1 software. Experiments were 
performed at least three times, with duplicate replicates. Expression levels are al-
ways given relative to GAPDH. PCR oligo sequences are listed in Table 4. 
 
Mice  
Ah-Cre mice and Apc
fl/fl
 mice were a kind gift of Alan R. Clarke (Sansom et al., 
2004). Ah-Cre mice were crossed with mice carrying the Apc floxed allele to 
yield Ah-Cre;Apc
fl/fl
 mice. For induction of the Ah promoter, Ah-Cre;Apc
+/+
 
control and Ah-Cre;Apc
fl/fl
 mice received three intraperitoneal injections of 10 
mg/kg each of the cytochrome p450 inducer "-naphthoflavone (Sigma) dissolved 
in corn oil (10 mg/ml). After 4 days, mice were sacrificed and livers were collec-
ted for further analysis. Mice were genotyped by PCR on tail genomic DNA e-
xtracted by standard procedures (Morsut et al., 2010). Effective recombination of 
the Apc locus was verified in the livers of mice injected with b-naphthoflavone.  
 
Immunoprecipitations 
Immunoprecipitations were carried out as in Adorno et al. (2009), with the follo-
wing modifications: extracts were diluted to 20 mM HEPES (pH 7.8), 100 mM 
NaCl, 5% glycerol, 2.5 mM MgCl2, 1% Triton X-100, 0.5% NP40 and incubated 
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with protein A-sepharose-bound primary antibody. 
For immunoprecipitations, primary antibody were: anti-TAZ monoclonal anti-
body (BD Biosciences), anti-"-catenin monoclonal antibody (Santa Cruz), and an-
ti-Flag-tag monoclonal antibody (M2, Sigma). 
 
Immunofluorescence  
Cells were plated on Fibronectin (Sigma)-coated glass chamber slides (Nunc) and 
fixed 10 min at room temperature (RT) with PFA 4%. Slides were permeabilized 
10 min at RT with PBS 0.3% Triton X-100, and processed for immu-
nofluorescence according to the following conditions: blocking in 10% BSA or 
Goat Serum (GS) in PBST for 1 hr, followed by incubation with primary antibody 
(diluted in 2% BSA or GS in PBST) for 16 hr at 4!C, four washes in PBST and 
incubation with secondary antibodies (diluted in 2% BSA or GS in PBST) for 1.5 
hr at room temperature. Primary antibodies are: anti-Scribble (Santa Cruz; 1:100, 
blocking with BSA), anti-E-Cadherin (BD Bioscences, 1:1000, blocking with 
GS), and anti-TAZ (BD Bioscences, 1:100, blocking with BSA). 
Secondary antibodies (Invitrogen) are: chicken anti-goat Alexa488 (1:100, blo-
cking with BSA) and goat anti-mouse Alexa488 (1:200, blocking with GS). After 
three washes in PBS, nuclei were stained with Hoechst (Sigma) for 30 min in 
PBS. Confocal images were obtained with a Leica TCS SP5 equipped with a CCD 
camera.  
 
GST Pull-Down  
For GST pull-downs, beads with purified proteins were incubated with 
35
S-
methionine labeled in vitro-translated "-catenin for 3 hr in Binding Buffer (25 
mM HEPES (pH 7.9), 0.4 M KCl, 0.4% NP40, 5 mM EDTA, 1 mM DTT, 10% 
glycerol with protease inhibitors). After 4 washes in binding buffer, copurified 
proteins were analyzed by SDS-page and autoradiography, using Cyclone Plus 
Phospho-imager (Perkin Elmer).  
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Table 1. Breast cancer datasets used in this study to build the metadataset. 
 
 
Study 
Affymetrix 
platform 
Samples Data source References 
Stockholm HG-U133A 159 GEO GSE1456 (Pawitan et al., 2005) 
Uppsala-Miller HG-U133A 236 GEO GSE3494 (Miller et al., 2005) 
Ivshina-Miller HG-U133A 249 GEO GSE4922 (Ivshina et al., 2006) 
Loi HG-U133A 327 GEO GSE6532 
(Loi et al., 2007; Loi et al., 
2008; Loi et al., 2010) 
Sotiriou HG-U133A 187 GEO GSE2990 (Sotiriou et al., 2006) 
Desmedt HG-U133A 198 GEO GSE7390 (Desmedt et al., 2007) 
Schmidt HG-U133A 200 GEO GSE11121 (Schmidt et al., 2008) 
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Table 2. Affymetrix probesets over-expressed more than two times in G3 as 
compared to G1 cancers of the metadataset. 
 
 
Probeset Gene Symbol Fold Change 
202870_s_at CDC20 3.17 
209773_s_at RRM2 3.26 
204825_at MELK 2.50 
202954_at UBE2C 2.46 
202705_at CCNB2 2.34 
210052_s_at TPX2 2.39 
208079_s_at AURKA 2.60 
218542_at CEP55 2.54 
202095_s_at BIRC5 2.64 
218355_at KIF4A 2.12 
204033_at TRIP13 2.31 
204962_s_at CENPA 2.57 
209408_at KIF2C 2.04 
222077_s_at RACGAP1 2.19 
218009_s_at PRC1 2.56 
201088_at KPNA2 2.08 
203764_at DLGAP5 2.45 
203418_at CCNA2 2.09 
218039_at NUSAP1 2.50 
209714_s_at CDKN3 2.39 
204822_at TTK 2.57 
203755_at BUB1B 2.00 
209642_at BUB1 2.20 
202580_x_at FOXM1 2.24 
201890_at RRM2 2.93 
206102_at GINS1 2.35 
203362_s_at MAD2L1 2.36 
210559_s_at CDC2 2.42 
203554_x_at PTTG1 2.12 
219918_s_at ASPM 2.61 
214710_s_at CCNB1 2.46 
202779_s_at UBE2S 2.35 
203213_at CDC2 2.38 
204641_at NEK2 2.23 
211762_s_at KPNA2 2.17 
203358_s_at EZH2 2.14 
204444_at KIF11 2.04 
220651_s_at MCM10 2.04 
217755_at HN1 2.16 
204170_s_at CKS2 2.43 
201195_s_at SLC7A5 2.44 
204026_s_at ZWINT 2.10 
207828_s_at CENPF 2.26 
201292_at TOP2A 2.67 
204162_at NDC80 2.12 
203214_x_at CDC2 2.05 
218662_s_at NCAPG 2.00 
201291_s_at TOP2A 3.00 
202589_at TYMS 2.16 
202503_s_at KIAA0101 2.10 
218883_s_at MLF1IP 2.33 
218585_s_at DTL 2.19 
219010_at C1orf106 2.29 
204533_at CXCL10 2.76 
219148_at PBK 2.18 
203560_at GGH 2.20 
202270_at GBP1 2.28 
215223_s_at SOD2 2.06 
204475_at MMP1 3.87 
203126_at IMPA2 2.04 
211122_s_at CXCL11 2.81 
210163_at CXCL11 2.78 
202269_x_at GBP1 2.41 
206632_s_at APOBEC3B 2.08 
202917_s_at S100A8 4.25 
204913_s_at SOX11 2.43 
206134_at ADAMDEC1 2.17 
203915_at CXCL9 2.53 
213975_s_at LYZ 2.03 
204914_s_at SOX11 2.09 
205347_s_at TMSB15A 2.05 
217388_s_at KYNU 2.21 
206392_s_at RARRES1 2.16 
220414_at CALML5 2.28 
216491_x_at IGHM 2.07 
203535_at S100A9 2.18 
204351_at S100P 2.37 
214777_at IGKV4-1 2.01 
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Table 3. RNAi sequences. Related to Experimental Procedures. 
 
 
siRNA/ 
shRNA 
Interfering sequence (target) Notes 
Control TTCTCCGAACGTGTCACGT   
GFP CAAGCTGACCCTGAAGTTC   
human     
TAZ#1 ACGTTGACTTAGGAACTTT 
TAZ#2 AGAGGTACTTCCTCAATCA 
TAZ#3 AGGTACTTCCTCAATCACA 
A mix of the three TAZ 
siRNAs was used, unless oth-
erwise specified. 
CAGGGAACTAGTCGCCATC (GSK3!) 
GSK3#1 
CCCAAATGTCAAACTACCA (GSK3") 
GAAGGTTCTCCAGGACAAG (GSK3!)  
GSK3#2 
AGTTGGTAGAAATAATCAA (GSK3") 
GSK3 siRNA#1 was used, 
unless otherwise specified. 
APC#1 GACGTTGCGAGAAGTTGGA 
APC#2 TAATGAACACTACAGATAG 
APC siRNA#1 was used, un-
less otherwise specified. 
GGGCATATCTGGATACCTG (Axin1) 
GGATACCTGCCGACCTTAA (Axin1) 
GAGTAGCCAAAGCGATCTA (Axin2) 
Axin  
CGATCCTGTTAATCCTTAT (Axin2) 
  
  
  
  
"-catenin#1 AGGTGCTATCTGTCTGCTC 
"-catenin#2 AACAGTCTTACCTGGACTC 
"-catenin#3 GTAGCTGATATTGATGGAC 
"-catenin#4 GCTTGGAATGAGACTGCTG 
A mix of "-catenin siRNAs #3 
and #4 was used, unless oth-
erwise specified.  
"-TrCP#1 
GTGGAATTTGTGGAACATC  
("-TrCP1 and "-TrCP2) 
GCGTTGTATTCGATTTGATAA ("-TrCP1) 
"-TrCP#2 
AAATGTCGGTACTTGAAGAGT ("-TrCP2) 
"-TrCP siRNA#1 was used, 
unless otherwise specified.  
#$catenin#1 AGTCGGCCATTGTGCATCT 
#$catenin#2 GGGCATCATGGAGGAGGAT 
#$catenin siRNA#1 was used, 
unless otherwise specified.  
LATS 
Dharmacon siGenome smart pool M-004632-00 
(LATS1) 
Dharmacon siGenome smart pool M-003865-02 
(LATS2) 
 
mouse     
TAZ TCATTGCGAGATTCGGCTG   
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Table 4. PCR oligo sequences. Related to Experimental Procedures. 
 
Gene Forward primer Reverse primer 
human     
GAPDH AGCCACATCGCTCAGACAC  GCCCAATACGACCAAATCC 
TAZ GGCTGGGAGATGACCTTCAC  CTGAGTGGGGTGGTTCTGCT 
APC GCCCCTGACCAAAAAGGAAC  TGGCAGCAACAGTCCCACTA 
Axin1 AGCCGTGTCGGACATGGA  AAGTAGTACGCCACAACGATGCT 
Axin2 TGTGAGGTCCACGGAAACTG  CGTCAGCGCATCACTGGATA 
CTGF AGGAGTGGGTGTGTGACGA  CCAGGCAGTTGGCTCTAATC 
Cyclin-D1 TCAAATGTGTGCAGAAGGAGGT  GACAGGAAGCGGTCCAGGTA 
mouse     
GAPDH ATCCTGCACCACCAACTGCT GGGCCATCCACAGTCTTCTG 
TAZ ATGAATCCGTCCTCGGTGC GAGTTGAAGAGGGCTTCGAG 
Flag-mTAZ ATGGACTACAAAGACGATGACG GAGTTGAAGAGGGCTTCGAG 
Cyr61 GCTCAGTCAGAAGGCAGACC GTTCTTGGGGACACAGAGGA 
CTGF CTGCCTACCGACTGGAAGAC CATTGGTAACTCGGGTGGAG 
Cyclin-D1 GACCTTTGTGGCCCTCTGTG AAAGTGCGTTGTGCGGTAGC 
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Figure 1. The Hippo pathway. 
(A) Schematic representation of the Hippo pathway components in flies (left 
panel) and vertebrates (right panel). Modified from Halder and Johnson, 2011. 
(B) Hippo mutant phenotype in flies. Images and scanning electron micrographs 
of a wild-type fly (Hippo wt) and a fly with clones of cells homozygous mutant 
for Hippo that exhibit overgrowth of the adult cuticle (Hippo mutant). Modified 
from Udan et al., 2003. 
(C-D) Hippo mutant phenotypes in mice. (C) Comparison between a mouse liver 
at 2 months of age from a wild-type animal and a liver at 2 months of age from a 
mouse mutant in which both Mst1 and Mst2 have been genetically inactivated. 
Modified from Zhou et al., 2009. (D) Comparison between a mouse heart from a 
wild-type animal and a heart from a Sav1 knockout mouse. Modified from 
Heallen et al., 2011. 
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Figure 2. YAP/TAZ signature correlate with high histological grades, 
stemness and metastasis in breast tumors. 
(A-B) Enrichment of gene signatures in the list of genes preferentially expressed 
in G3 versus G1 tumors in the metadataset. (A) Scheme of the computational pro-
cedure used to generate the data reported on the right. (B) Numbers indicate p-
values (corrected for multiple tests) for significance of the enrichment. Signatures 
significantly enriched in G3 tumors (p-value < 0.05) are indicated in bold. ‘‘No 
overlap’’ indicates the absence of genes in common between the indicated signa-
ture and the genes overexpressed in G3 tumors. 
(C) Average gene-expression values of signatures for normal mammary 
(hNMSC), breast cancer (IGS, CD44high), and embryonic (ES1, ES2, ES-like) 
stem cells in breast tumor samples stratified according to histological grading. G2 
tumors were stratified in two groups according to high or low expression of the 
TAZ/YAP signature. Average gene-expression values of the TAZ/YAP signature 
(lane 1) are shown as control of the procedure. Data are shown as mean ± SEM.  
(D) Kaplan-Meier graphs representing the probability of cumulative metastasis-
free survival in breast cancer patients from the metadataset stratified according to 
the TAZ/YAP signature. The log-rank test p-value reflects the significance of the 
association between TAZ/YAP signature ‘‘Low’’ and longer survival.  
Figure 2
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Figure 3. Validation of the MII-MIV cell lines as model for increased CSC 
content and TAZ level 
(A) Schematic representation of the MCF10A-MII-MIV cellular model. 
(B) Quantification of primary and secondary mammospheres formed by MII or 
MIV cells (mean + SEM of six experiments). 
(C) Representative hematoxylin and eosin staining of  tumors emerging after fat 
pad injection of RAG-/-!mice with MII or MIV cell lines. 
(D) Tumor seeding ability of MII and MIV. The indicated number of cells was in-
jected in the fat pad of RAG
-/-
 mice. The table reports data as the number of mice 
developing palpable tumors after five weeks / the number of injected mice. 
(E) Western blot analysis for YAP, TAZ and GAPDH (loading control) in lysates 
from the MII, MIV and MDA-MB-231 cells. 
(F) Western blot analysis for TAZ and CTGF in lysates from control (shControl) 
and TAZ-depleted (shTAZ) MIV cells.  
(G) Quantification of primary and secondary mammospheres formed by shControl 
or shTAZ MIV cells (mean + SEM of six experiments).  
(H-I) Effects of TAZ reconstitution in MIV-shTAZ cells. MIV-shTAZ cells were 
transduced with a rtTA-encoding lentiviral vector in combination with tetracycli-
ne-inducible vectors encoding EGFP or wild-type mouse TAZ (mTAZ). The two 
resulting cell lines (MIV-shTAZ+EGFP, MIV-shTAZ +mTAZ) were treated with 
doxycycline (0.1 mg/ml) and compared with shControl and parental shTAZ MIV 
cells. (H) Western blot analysis for TAZ and CTGF in lysates from the indicated 
cell lines. (I) Quantification of primary mammospheres formed by the cell lines 
described above (mean + SEM of six experiments).  
(J) Tumor-seeding ability of shControl and shTAZ MIV cells. The indicated 
number of cells were injected into the fat pads of SCID mice. Palpable tumor 
formation was evaluated 3 weeks after transplantation. Results are shown as the 
fraction of mice developing palpable tumors.  
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Figure 4. TAZ protein level and activity is elevated in CD44high subpopula-
tion of MII cells and sustain their self-renewal capacities 
(A) FACS profile of MII cells with CD24 and CD44 markers. MII cells presented 
two distinct subpopulation (first panel on the left): CD44
Low
CD24
Low
 (green) and 
CD44
High
CD24
Low
 (red). Once sorted (sorting efficiency is shown in the middle 
panels) and cultured for a month, the CD44
High
CD24
Low
 can recreate the entire 
MII population, whereas the CD44
Low
CD24
Low
 can not. 
(B) Western blot analysis for expression of TAZ, CTGF and Survivin in the 
CD44
Low
CD24
Low
 and CD44
High
CD24
Low
 populations from FACS-sorted MII 
cells.  
(C) Hoechst-33342 staining of MII cells. Left panel: Representative FACS profile 
of MII cells stained with Hoechst-33342. The SP cells are shown in green. Right 
panel: Distribution of SP cells according to CD44 expression. The large majority 
(86%) of the SP is in the CD44
High
CD24
Low
 population.  
(D) Quantification of secondary mammospheres formed by CD44
Low
CD24
Low
 and 
CD44
High
CD24
Low
 MII cells (mean + SEM of six experiments). MII cell popula-
tions were purified by FACS, amplified in 2D culture and used for mammosphere 
formation.  
(E) Western blot analysis for TAZ in lysates from control (shGFP) and TAZ-
depleted (shTAZ) MII cells.  
(F) Effects of TAZ depletion on CD44
High
 subpopulation in MII cells. Left: repre-
sentative FACS profiles of shGFP or shTAZ#1 MII cells. Right: quantification of 
CD44
High
 subpopulation in the indicated cell lines. 
(G) Quantification of secondary mammospheres formed by shGFP- and shTAZ-
MII cells (mean + SEM of six experiments). 
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Figure 5. TAZ confers self-renewal capacities to breast cancer cells 
(A) Western blot analysis for TAZ, CTGF, PAI-1 and Survivin in control (Empty 
vector) and TAZ S89A-expressing MII cells.  
(B) Quantification of primary, secondary and tertiary mammospheres formed by 
MII-empty vector or MII-TAZ S89A cells (mean + SEM of six experiments). 
(C) Representative FACS profiles with CD24 and CD44 markers of MII cells 
transduced with control (empty vector) or TAZ S89A-encoding retroviral vectors, 
and, as comparison, of MIV and MDA-MB-231 cells 
(D-E) Forced expression of TAZ increase mammosphere capacity of 
CD44
Low
CD24
Low
. MII cells were transduced with vectors encoding for the rever-
se tetracycline-dependent transactivator (rtTA) and for a doxycycline-inducible 
TAZ S89A or EGFP and FACS-sorted according to their CD44
Low
CD24
Low
 or 
CD44
How
CD24
Low
 profile. Each subpopulation was then left untreated or treated 
with doxycycline (0.5 µg/ml) to induce either TAZ S89A or EGFP, and then te-
sted for mammosphere formation. (D) Schematic representation of the experi-
ment. (E) Quantification of secondary mammospheres formed by the subpopula-
tion of MII cells described above (mean + SEM of six experiments). 
A B C
D E
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Figure 6. TAZ confers resistance to chemotherapy to breast cancer cells 
(A) Representative FACS profile of MII-Empty vector and MII-TAZ S89A cells 
stained with Hoechst-33342. The exclusion of the Hoechst dye in MII-TAZ S89A 
cells is blocked by Verapamil. 
(B) Quantification of the Side population of the cells described in (A). 
(C) Dose-response curves of MII-Empty vector and MII-TAZ S89A cells treated 
with Paclitaxel. Bars denote the standard error (n = 4).  
(D) Dose-response curves of MII-Empty vector and MII-TAZ S89A cells treated 
with Doxorubicin. Bars denote the standard error (n = 4).  
A B
C D
Figure 6
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Figure 7. TAZ promotes the formation of high-grade breast cancers 
(A) Frequency of TAZ-positive G1 or G3 primary human breast cancers as judged 
by immunohistochemistry (IHC). Tumors were scored as positive when over 10% 
of cells displayed nuclear TAZ staining similar to or stronger than that of the cells 
of normal ducts included in the same section. 35/44 G3 tumors and only 1/26 G1 
tumor were found positive for TAZ expression (p value < 0.0001). 
(B-C) Representative IHC pictures for TAZ expression in G1 (A) or G3 (B) inva-
sive human breast cancer samples. Nuclei are counterstained with hematoxylin. 
Black arrowheads in (A) point to the TAZ-positive cells of the normal mammary 
ductal tissue (NT) included in the same section with G1 tumor structures (G1). In-
set in (A) shows (white arrowhead) very rare TAZ-positive cells that are seldom 
associated with G1 tumors. 
 (D) Tumor seeding ability of MII-empty vector and MII-TAZ S89A cells. The 
indicated number of cells was injected in the fat pad of RAG
-/-
 mice. The table re-
ports data as the number of mice developing palpable tumors after five weeks / 
the number of injected mice. 
(E-F) Representative hematoxylin and eosin staining of tumors emerging from 
fat-pad injection of MII-empty vector (E) and MII-TAZ S89A cells (F).  
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Figure 8. Summary of the results reported in Part 1 
Schematic representation of the results presented in Part 1 regarding the role of 
TAZ in breast tumor as cancer stem cell determinant. 
Figure 8
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Figure 9. Wnt signaling promotes TAZ stabilization and activation 
(A) HEK293 cells were transfected with the indicated siRNAs and either left un-
treated (control conditioned medium, Co) or treated with Wnt3A-conditioned me-
dium for 24 hr. Where indicated, the Wnt inhibitor XAV939 (1 µM) was added to 
the medium. Top panel: Luciferase assay with 8xGTIIC reporter. Bars are mean + 
SD. Bottom panel: western blot for TAZ, YAP, "-catenin and GAPDH (loading 
control) in the extracts used for the luciferase assay. 
(B) qRT-PCR for TAZ mRNA expression in HEK293 cells left untreated (control 
conditioned medium, Co) or treated with Wnt3A-conditioned medium for 24 hr. 
Data were normalized to control-treated cells; bars are mean + SD.  
(C) Validation of Wnt activity using the "-catenin/TCF-luciferase reporter (BAT-
Lux). HEK293 cells were transfected with BAT-Lux and with Control or "-
catenin siRNAs, and either left untreated (Co) or treated with Wnt3A-conditioned 
medium for 24 hr. Where indicated, the Wnt inhibitor XAV939 (1 µM) was added 
to the medium.  Data are normalized to lane 1 and are presented as mean + SD.  
(D) HEK293 cells were transfected with the indicated siRNAs and used for a lu-
ciferase assay on 8xGTIIC reporter (top panel). Bars are mean + SD. 
(E) HEK293 cells were transfected with Control, GSK3, APC or Axin siRNAs, 
either alone or with TAZ siRNA, and used for a luciferase assay on 8xGTIIC re-
porter (top panel) or for western blot analysis (bottom panel). Bars are mean + 
SD. 
(F) Luciferase assay on BAT-Lux reporter recording the "-catenin transcriptional 
activity in HEK293 cells transiently transfected with Control, GSK3, APC or A-
xin siRNAs, either alone or in combination with "-catenin siRNA. Data are nor-
malized to lane 1 and are presented as mean + SD.  
(G) HEK293 cells were transfected with Control or LATS siRNAs, and either left 
untreated (control conditioned medium, Co) or treated with Wnt3A-conditioned 
medium for 24 hr. Top panel: Luciferase reporter assay of the indicated samples. 
Data are normalized to lane 1 and are presented as mean + SD. Bottom panel: we-
stern blot for TAZ in the same extracts used above. 
(H) Luciferase assay on 8xGTIIC reporter recording the transcriptional activity of 
mouse wild-type TAZ or TAZ 4SA transiently transfected in HEK293 cells, in the 
absence (Co) or presence (Wnt3A) of Wnt stimulation. Cells were transfected 
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with TAZ siRNA to avoid interference from regulations of endogenous TAZ. Top 
panel: Luciferase reporter assay of the indicated samples. Data are normalized to 
lane 1 and are presented as mean + SD. Bottom panel: representative western blot 
for TAZ in the same extracts used for the luciferase assay.  
(I-J) TAZ levels and expression of Cyr61, CTGF and Cyclin-D1 in control and 
APC deficient mouse livers, as evaluated by western blot or qRT-PCR. 
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Figure 10.  GSK3 mediates TAZ degradation 
(A) !-TrCP depletion leads to TAZ stabilization in MII cells, as revealed by west-
ern blot. 
(B) Top panel: Luciferase assay on 8xGTIIC reporter recording TAZ transcriptio-
nal activity in HEK293 cells transfected with Control siRNA or two independent 
siRNAs targeting !-TrCP, with or without TAZ siRNA. Where indicated, a con-
struct encoding a dominant-negative version of human Cullin1 was transfected 
together with the reporter (lanes 7 and 8). Data are normalized to lane 1 and bars 
are mean + SD. Bottom panel: western blot for TAZ expression in the same e-
xtracts used for the luciferase assay. 
(C) Endogenous TAZ binds to !-TrCP in a GSK3-dependent manner. Co-
immunoprecipitation and western blot analysis of MII cell lysates shows that en-
dogenous !-TrCP is pulled-down specifically by TAZ (lane 1 vs 2), only in the 
presence of GSK3 (lane 2 vs 3). 
(D) GSK3 kinase activity is essential to dampen TAZ protein levels and function. 
MII cells were engineered to express doxycycline-inducible/siRNA-insensitive 
human GSK3b, either wild-type (wt; lanes 1-3) or kinase-dead mutant (KD; lanes 
4-6). After depletion of endogenous GSK3 by siRNA transfection (lanes 2, 3, 5 
and 6), cells were exposed to 0.5 µg/ml doxycycline to induce the expression of 
either wt GSK3! (lane 3) or KD GSK3! (lane 6). Lanes 1 and 4 are cells trans-
fected with Control siRNA. Top panel: qRT-PCRs for CTGF (mean + SD). Bot-
tom panels: western blots for TAZ and GSK3. Lane 1 vs. 2 and Lane 4 vs. 5: TAZ 
is stabilized and activated (CTGF induction) upon GSK3 depletion; lane 3: recon-
stitution with wt GSK3! rescues the effect of GSK3 depletion; lane 6: reconstitu-
tion with KD GSK3! has no effect. 
(E) Top panel: luciferase assay on 8xGTIIC reporter in HEK293 cells transiently 
transfected with Control siRNA (lanes 1) or with siRNAs targeting GSK3 (lanes 
2-4). Where indicated, constructs encoding siRNA-insensitive GSK3! wt (lane 3) 
or GSK3! KD (lane 4) were transfected together with the reporter. Data are nor-
malized to lane 1 and bars are mean + SD. Bottom panel: western blots for TAZ 
and GSK3 expression in the same extracts used for the luciferase assay.  
(F) Comparison of the GSK3-dependent phosphodegrons of TAZ, !-catenin and 
other proteins known to be regulated by GSK3 and !-TrCP. Aminoacids essential 
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for binding to !-TrCP are indicated in red. 
(G) GSK3 regulates TAZ independently of its phosphodegron. Lanes 1-2: West-
ern blot for endogenous TAZ shows its stabilization upon GSK3 depletion. Lanes 
3-6: MII cells were transfected with TAZ siRNA (to avoid interference from regu-
lations of endogenous TAZ) and reconstituted with siRNA-insensitive mouse 
TAZ, either wild-type (wt, lanes 3-4) or S58/62A mutant (lanes 5-6). Both wt and 
S58/62A TAZ are sensitive to GSK3 siRNA. 
(H) Wnt activates TAZ independently of its GSK3-phosphodegron. HEK293 cells 
were transfected with the synthetic 8xGTIIC-Lux reporter. Lanes 1-2: Wnt3A 
conditioned medium activates the reporter. Lanes 3-4: knockdown of endogenous 
TAZ abolishes the effect of Wnt. Lanes 5-8: cells were transfected with TAZ 
siRNA to avoid interference from regulations of endogenous TAZ and reconsti-
tuted with either mouse wild-type TAZ (wt, lanes 5-6) or TAZ S58/62A (lanes 7-
8). The phosphodegron is irrelevant for TAZ activation by Wnt (lanes 6 and 8). 
Bars are mean + SD. 
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Figure 11.  !-catenin mediates TAZ degradation 
(A-B) !-catenin associates with TAZ at endogenous protein levels. 
(C) !-catenin is required for TAZ interaction with !-TrCP. Endogenous TAZ was 
immunoprecipitated from lysates of MII cells transfected with Control, !-catenin 
or TAZ siRNAs, using anti-TAZ antibody, and co-precipitating proteins were de-
tected by western blot. 
(D) Endogenous !-catenin is required for TAZ degradation. MII cells were trans-
fected with Control or !-catenin siRNAs. Top panel: qRT-PCRs for TAZ target 
CTGF. Bars are mean + SD, normalized to lane 1. Bottom panels: western blots 
for TAZ and !-catenin. GAPDH serves as loading control. TAZ mRNA expres-
sion wasn’t affected by !-catenin depletion (data not shown). 
(E) Luciferase assay on 8xGTIIC reporter in HEK293 cells transfected with Con-
trol or !-catenin siRNAs, with or without TAZ siRNA. Data are normalized to 
Control siRNA-transfected cells and bars are mean + SD. 
(F) Representative confocal images of TAZ, Scribble and E-cadherin in MII cells 
transfected with Control or !-catenin siRNAs. Nuclei are stained with Hoechst. 
(G) Western blots for total and Serine 909-phosphorylated LATS1 in MII cells 
transfected with Control or independent !-catenin siRNAs.  
(H) Phospho-!-catenin mediates TAZ degradation. MII cells were engineered to 
express doxycycline-inducible siRNA-insensitive !-catenin, either wild-type (wt; 
lanes 1-3) or phospho-mutant (S/A, lanes 4-6). After depletion of endogenous !-
catenin by siRNA (lanes 2, 3, 5 and 6), cells were treated with 0.5 µg/ml doxycy-
cline to induce the expression of wt (lane 3) or S/A !-catenin (lane 6). Lanes 1 
and 4 were cells transfected with Control siRNA. Panels are western blots for 
TAZ, CTGF and !-catenin. Lane 1 vs. 2, and Lane 4 vs. 5: TAZ is stabilized and 
activated upon !-catenin depletion; lane 3: reconstitution with wt !-catenin res-
cues TAZ inhibition; lane 6: S/A !-catenin cannot revert the effect of !-catenin 
siRNA. 
(I) Scheme of the two transcripts (and protein products) encoded by the wild type 
(wt, black) and exon3/exon4-deleted (del ex3-4, blue) !-catenin alleles of HepG2 
cells. The phosphodegron site on wild-type !-catenin, missing in the mutant pro-
tein, is in orange. The regions of !-catenin mRNA targeted by siRNAs are indi-
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cated in red: as the sequence targeted by siRNA#4 is within the deletion, this 
siRNA only hits the wild-type transcripts, whereas siRNA#3 is used to deplete 
both isoforms.  
(J) HepG2 cells were transfected with !-catenin siRNAs indicated in (I), with or 
without TAZ siRNA. Top panel: qRT-PCRs for CTGF. Bars are mean + SD, 
normalized to lane 1. Bottom panels: western blots for TAZ and !-catenin.  
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Figure 12.  The WW domain of TAZ is necessary for the interaction with !-
catenin 
(A) Schematic representation of GST-TAZ deletion constructs used for the GST-
pulldown in (B). TB: TEAD binding domain; TA: Transcriptional Activation do-
main; PB: PDZ-binding motif.  
(B) Autoradiography of in vitro-translated 
35
S-!-catenin pulled-down by the indi-
cated GST-TAZ deletion constructs immobilized on a glutathione-resin. GST pro-
tein was used as a negative control. The lane labeled as ‘‘Input’’ represents 1/100 
of 
35
S-!-catenin used for the pull down experiments. 
(C) Western blot for TAZ in MII cells depleted of endogenous TAZ and transdu-
ced with wild-type or "WW TAZ. TAZ "WW is more stable than the wild-type 
protein, despite the fact that both the N-terminal (S58 and S62) and the C-terminal 
(S309) phosphodegrons are not affected by the deletion of the WW domain, as 
shown in the scheme above the blot (abbreviations are as in A).  
(D) The WW domain of TAZ is required for association to !-catenin and !-TrCP. 
TAZ was immunoprecipitated from lysates of MII cells stably expressing Flag-
tagged wild-type or "WW TAZ using anti-Flag antibody, and co-precipitating 
proteins were detected by western blot. 
(E) Luciferase assay on 8xGTIIC reporter recording the transcriptional activity of 
wild-type or "WW TAZ transiently transfected in HEK293 cells, in the absence 
(Co) or presence (Wnt3A) of Wnt stimulation. Cells were transfected with TAZ 
siRNA to avoid interference from regulations of endogenous TAZ. Data are nor-
malized to lane 1 and are presented as mean + SD. Bottom panel: western blots 
for TAZ in the same extracts used for the luciferase assay. 
(F) TAZ "WW is phosphorylated at Serine 306. MII cells were depleted of endo-
genous TAZ and transduced with mouse TAZ (siRNA-insensitive) wild-type, 
S306A or "WW. TAZ was immunoprecipitated with an anti-TAZ antibody and 
phosphorylation on S306 was detected on the immunoprecipitated protein using a 
specific antiserum raised in rabbit. TAZ S306A mutant was used as negative 
control for the antiserum.  
(G) TAZ "WW is sensitive to LATS inhibition. MII cells depleted of endogenous 
TAZ were transduced with wild-type, "WW or 4SA TAZ, and transfected with 
Control or LATS siRNAs. TAZ levels were evaluated by western blot.  
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Figure 13.  #-catenin mediates TAZ degradation 
(A) Co-immunoprecipitation between endogenous TAZ and #-catenin in MII cell 
lysates.  
(B) The WW domain of TAZ is required for association to #-catenin. MII cells 
stably expressing Flag-tagged wild-type or "WW TAZ were cultured at high cell 
density and then harvested for protein extraction. TAZ was immunoprecipitated 
from the cell lysates using anti-Flag antibody, and co-precipitating proteins were 
detected by western blot.  
(C) Western blots for TAZ and #-catenin in extracts from HEK293 cells trans-
fected with Control or #$catenin siRNA.  
(D-E) Luciferase assay on 8xGTIIC reporter in HEK293 cells transfected with 
Control, !-catenin (si!cat #1 in D or #2 in E) or #-catenin (si#cat) siRNAs as indi-
cated, with or without TAZ siRNA. Data are normalized to Control siRNA-
transfected cells and bars are mean + SD. Similar results were obtained with two 
different !-catenin or #-catenin (data not shown) interfering sequences. 
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Figure 14. The Wnt pathway and the new perspective on Wnt pathway re-
ported in Part 2 
(A) Schematic representation of canonical Wnt pathway. 
(B) Schematic representation of the Wnt pathway and the Wnt/TAZ connection 
that we reported in Part 2. 
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